CURRICULUM VITAE

Name: Scott Laurence Friedman Date of Birth: June 13, 1955 Place of Birth: Brooklyn, New York Education: 1976 B.S. Rensselaer Polytechnic Institute (Cum Laude), Troy, New York 1979 M.D. Mount Sinai School of Medicine, New York, New York Postdoctoral Training: Internship and Residency: 1979-1980 Intern in Medicine, Beth Israel Hospital, Boston 1980-1982 Junior & Senior Resident, Internal Medicine, Beth Israel Hospital, Boston Fellowship: 1982-1983 Clinical Fellow in Gastroenterology, Univ. of California, San Francisco

1983-1986 Research Fellow in Gastroenterology, Univ. of California, San Francisco

Leadership Training: 2005 Leadership Development for Physicians in Academic Health Centers,

Harvard School of Public Health, Boston (2 week course) Research Training: 1975 Undergraduate Thesis, Rensselaer Polytechnic Institute 1977 Clinical Research in Liver Disease, Prof. Sheila Sherlock, Royal Free Hospital, London 1983-1986 Research Fellow in The Rice Liver Center Laboratory, University of California San Francisco

Scott L. Friedman

2

Licensure: 1980 Massachusetts License, Registration No. 47438 1980 Diplomate, National Board of Medical Examiners, No. 212078 1981 Drug Enforcement Administration, No. AF1046843 1982 California License, No. G47570 1982 American Board of Internal Medicine, Certificate No. 85068 1985 Diplomate in Gastroenterology 1997 New York License, No. 209131 Academic Appointments: 1979-1982 Clinical Fellow in Medicine, Harvard Medical School 1982-1983 Clinical Fellow in GI, University of California, San Francisco 1982-1986 Postdoctoral Scholar, University of California, San Francisco 1986-1992 Assistant Professor of Medicine, UCSF 1992-1997 Associate Professor of Medicine, UCSF 1995-1996 Visiting Professor, Weizmann Institute of Science, Rehovot, Israel (Host: Prof. Moshe Oren, Dept of Molecular Cell Biology) 1997- Professor of Medicine & Director of Liver Research, Mount Sinai School of Medicine, New York

1998-1999 Graduate Faculty in Biomedical Sciences, City University of NY 1998- Graduate Faculty in Biomedical Sciences, New York University

2001- Director, Division of Liver Diseases, Mount Sinai School of Medicine 2012- Dean for Therapeutic Discovery

Hospital Appointments: 1986-97 Attending Physician, San Francisco General and Moffitt Hospitals 1992-94 Director, Gastrointestinal Clinic, San Francisco General Hospital

1997- Attending Physician, Mount Sinai Hospital, New York 2001- Chief, Division of Liver Diseases

Awards and Honors: 1975 Phi Lambda Upsilon Chemical National Honorary Society 1978 Alpha Omega Alpha, Lambda Chapter, Chapter President, 1978 1979 Arthur H. Aufses Sr., Prize in Surgery, Mount Sinai School of Medicine 1985 Giannini Foundation Research Fellowship (declined) 1985 National Institutes of Health, Research Service Award #F32 SM07589-01 1985 Am. Gastro Assn. Research Training Supplement Award 1986 American Gastroenterological Assn. Research/Industry Scholar Award 1986 UCSF Academic Senate Research Award 1989 UCSF Research, Education and Allocation Committee Award 1990 American Heart Assn. Grant-in-Aid Award

Scott L. Friedman

3

1992 Listed among "Bay Area's Best Doctors", San Francisco Focus Magazine 1993 Saul Horowitz Outstanding Alumnus Award, Mt Sinai School of Medicine 1995 Fulbright Senior Scholar Award

1998 Irene and Dr. Arthur Fishberg Professor of Medicine, Mount Sinai 1999 Charles Flood Memorial Lecture, NY Cornell Presbyterian Hosp. GI Division 2000 Ernest Hafter Memorial Lecture, Swiss Gastroenterological Assn.

2000 Tisdale Invited Professor, University of Vermont School of Medicine. 2001 Jacobson Visiting Professor and Lecturer, U. of Newcastle School of

Medicine 2003 Cecil Watson Lecturer, U. Minnesota 2003 International Hans Popper Award to Outstanding Researcher in Hepatology 2004 Lieberman Memorial Lecture, Lenox Hill Hosp.,Dept of Medicine, NY, NY. 2005 Hack Distinguished Lecturer, Stanford U. Gastroenterology Division 2005 John Carbone Visiting Professor, UCSF Gastroenterology Division 2006 Hewlett High School Alumni Hall of Fame 2004 America’s Top Doctors

2005 AstraZeneca Visiting Professor, U. of Michigan Gastroenterology Division 2005 Governing Board, Am Assn for the Study of Liver Diseases 2006 Atkinson Lecture, Northwestern U. Department of Medicine 2006 Alpha Omega Alpha, Honorary Student-nominated member 2006 Hans Popper Memorial Lecture, Intl. Assn for Study of Liver, Cairo, Egypt 2006 Solomon Berson Dept of Medicine Housestaff Teaching Award, Mount Sinai

School of Medicine 2007 Advisory Professor, Fudan University, Shanghai

2007 Zetzel Visiting Professor of Gastroenterology, Beth Israel Deaconess Hospital, Boston, MA.

2008 Sackler Distinguished Lectureship, Tel Aviv University, Israel 2008, 2010 “America’s Top Physicians” listing

2008 Fellow of the American Gastroenterological Assn 2008 DeGraff Memorial Lecture, NYU Langone School of Medicine, Research Day 2008 Dean’s Distinguished Lecturer, Georgetown U. School of Medicine 2009 Castle Connally ‘Top Doctors’ Selection 2009 Klatskin Memorial Lecture, Yale Liver Center and Digestive Disease Section 2009 Lumeng Honorary Lecture, Indiana U. School of Medicine, GI Division 2009 Mount Sinai Senior Faculty Council Award for Academic Excellence 2009 Shanghai City Magnolia Memorial Award 2009 President, American Assn for the Study of Liver Disease 2009 Master Educator Status, Mount Sinai Institute for Medical Education 2009 Rafael Research Alumni Visiting Scientist, Rambam Hospital, Haifa, Israel 2010 Sheila Sherlock Lecture, British Assn for Gastroenterology, Liverpool, UK 2010 Englert Lecture, University of Utah Dept of Medicine 2010 Ken & Louise Goldberg Visiting Professor, Brigham and Women’s Hospital

Scott L. Friedman

4

Major Committee Assignments: Mount Sinai School of Medicine 1978-1979 Admissions Committee 1998- MSTP Admissions Committee 1998- Department of Medicine Research Committee 1999- Chair, Pulmonary Search Committee 1999- Medical Student Research Advisory Committee 1999- Member, Biochemistry & Molecular Biology Search Committee 1999- Institutional Industrial Liaison Committee

2000 Translational Research Facility Advisory Committee 2000 Space allocation committee 2002 Dept of Medicine Chairman Search Committee

2002 Chair, Dept of Medicine Appointments and Promotion Committee 2002 Steering committee and preceptor, NIH Pharmacology Training Grant 2003 Preceptor, NIH Cancer Center Training Grant 2003 Oncology Working Group, Institutional Cancer initiative 2003 Conflict of Interest in Research Committee 2003 Committee on Scientific Awards (COSA) 2004 Stem Cell Center, Associate Member 2005 Student Promotions Committee 2005 Doris Duke Fellow Selection Committee 2005 Dean’s Research Working Groups – Liver and Metabolic Diseases (co-chair) 2005 Educational Enterprise Strategic Planning Committee 2006 Curriculum Content Review Task Force 2006 Committee for Ethical Practices in Research

2009 Office for Women’s Careers Advisory Committee 2009 Oversight Committee for Curriculum Reform

University of California, San Francisco 1984-86 Nutrition Support Committee 1987-97 Fellowship Selection Committee, Gastroenterology Division 1988-97 UCSF Gastroenterology Division Seminar Series Committee 1989-97 UCSF Liver Center Executive Committee 1990-97 Director, Gastroenterology Division Fellow's Course 1991-97 Dept. of Medicine Intern Selection Committee 1993-95 Institutional Resources and Support Services Committee 1994-97 Research Evaluation and Allocation Committee Memberships in Professional Societies: 1982 American Gastroenterological Association 1984 American Federation for Clinical Research 1987 American Assn. for the Study of Liver Diseases

Scott L. Friedman

5

1988 American College of Physicians 1990 American Society of Cell Biology 1991 Western Society for Clinical Investigation 1991 International Assn. for the Study of the Liver 1995 American Society for Clinical Investigation (ASCI) 1996 Fulbright Association 2004 Association of American Physicians (AAP) 2006 European Assn. for the Study of the Liver

Service to Public and Non-Profit Agencies: 1987- Veteran's Administration, Ad Hoc Grant Reviewer. 1988 NIH Workshop, Potomac, MD on "Mucosal Immunity in AIDS". 1989 Co-organizer, AASLD Spring Research Conference, Monterey, CA. "Connective tissue biology of the liver". 1989-97 Editorial Board, Hepatology 1986- Journal Reviewer:

New England Journal of Medicine Science Nature Nature Genetics Annals of Internal Medicine Gastroenterology Hepatology Cell Metabolism

Molecular and Cellular Biology Oncogene Journal of Clinical Investigation American Journal of Pathology LaboratoryInvestigation Journal of Cell Biology Biochimica et Biophysica acta

1990- Abstract Selection Committee, AASLD & AGA Annual Meetings 1991-94 Publications Committee, AASLD 1995- Board of Governors, US-Israel Binational Science Foundation 1996-99 Clinical Teaching Project, Am. Gastroenterological Assn. 1996- Grant reviewer, Israel Science Foundation 1996- Editorial Board, Journal of Gastroenterology and Hepatology 1996-2001 Associate Editor, Hepatology 1998-99 Nominating Committee, AASLD 1998-2001 Training and Workforce Committee, AASLD 1998- NIDDK SRC-C Study Section, ad hoc member 1999- Wellcome Trust, UK; Ad hoc reviewer, 2000- NIDDK, AA-1 Study section, ad hoc member 2000-2003 Editorial Board, American Journal of Physiology 2000-2003 Editorial Board, Journal of Gastroenterology and Hepatology

2001- Scientific Advisory Board, Yale University School of Medicine Liver Center 2001- Councilor, Liver Section, AGA 2001- Nominating Committee, AGA 2001- NIDDK, Special review Committee for RFA 01-023, “Development of the

Gut, Liver and Exocrine Pancreas” 2000 Medical Research Council, UK; Ad hoc reviewer

Scott L. Friedman

6

2000- Publications Committee, AGA 2002- NIDDK, GMA-2 Study Section; Ad hoc reviewer.

2002- Editorial Board, Gut 2002- Publications Committee, AASLD 2002- Editorial Board, Hepatology Research 2003- AGA Committee on Gastroenterology Research 2003 Editorial Board, Gastroenterology 2003- German Network of Competence for Viral Hepatitis; Ad hoc reviewer 2003- Hong Kong Research Grants Council, Ad hoc reviewer 2003- Canadian Liver Foundation, Ad hoc reviewer 2003- NIH Experienced Reviewer Reserve 2003- FWO Dutch Research Council, Ad hoc reviewer 2003- Editorial Board, Comparative Hepatology 2004-2007 Editorial Board, Journal of Hepatology 2004 NIDDK Advisory Panel for Liver Disease Research Action Plan

2004 Review panel, Doris Duke Charitable Foundation Clinical Scientist Award 2004- AASLD Council (AASLD President in 2009) 2005- European Assn. for the Study of the Liver, Ad hoc Grant Reviewer 2005- NIDDK Board of Scientific Counselors Review 2005- Editorial Board, World Journal of Gastroenterology 2006- Cancer Research UK, Ad hoc reviewer 2006- INSERM, Ad hoc reviewer

2006- Organizer, AASLD Single Topic Conference on Hepatic Fibrosis 2007- Editorial Board, Liver Transplantation 2007- NIH, DDK-C Study Section, Ad hoc reviewer 2008- NIAAA Advisory Council 2008- Oral expert testimony to NIH Scientific Management Review Board University Service and Teaching:

1986-97 Attending Physician, Medical and Gastroenterology Service 1989-97 Mentor, Gastroenterology Research Fellows 1990-97 Director, First-year Medical Student Liver Pathophysiology mini-course 1991-97 Faculty, Molecular Medicine Program 1994-96 Director, UCSF Gastroenterology Division Postgraduate Course 1994-96 Mentor, Medical Student Research Fellow, Howard Hughes Medical Inst. 1996 Graduate Course Director, Feinberg Graduate School, "The liver as a model organ: molecular and clinical aspects. Weizmann Inst. of Science 1997 Faculty, UCSF Biomedical Science Program. “Liver function & disease”

1997- Faculty, Mount Sinai School of Medicine Graduate Program 1999- Steering Committee, “Mechanisms of Disease & Therapy” graduate program 1999- Mentor, MSSM Morchand Center 4th year clinical skills assessment program 1999- Mount Sinai Office of Student Research Opportunities Advisory Committee

2007- Assistant Director, Mount Sinai MSTP Program 2009 Associate Director, Mount Sinai K12 Research Scholars Program

Scott L. Friedman

7

Major Research Interests: • Cellular and molecular mechanisms of hepatic fibrosis and cancer • KLF6 tumor suppressor gene in cancer pathogenesis, diagnosis and treatment • Diagnosis and development of anti-fibrotic therapies for patients with chronic liver disease • Alcoholic liver disease – pathogenesis and treatment

Past and Current Trainees

Medical and Graduate Students:

° Susan Jensen, M.D. (1994-96), Medical Student. Awardee: Howard Hughes Med Inst. Medical Student Research Fellowship. Current status: Staff Scientist, Food & Drug Adminstration

° Nhat Pham (1997). UCSF Summer Research Medical Student. ° Goutham Narla (1998- 2006), Medical Student, then MSTP Student. First prize

winner, NIH/AMSA student research contest, Chicago, IL 2/99. Awardee: American Liver Foundation Student Research Grant; Howard Hughes Medical Student Fellowship; Current status: Houseoffice, Medical Genetics, Mount Sinai Hospital.

° Simon Beaven, MD (1998-2000), Medical Student. Awardee: Am Assn. for the Study of Liver Diseases (AASLD) Student Research Prize, UCSF Dean’s Research Prize, 2001. Howard Hughes Med Inst. Medical Student Research Fellowship; Current status: Assistant Professor of Medicine, Geffen UCLA School of Medicine, LA.

° Lawrence Cicchiello,. M.D. (1999 - 2000) Medical Student; Awardee: ALF Student Summer Research Fellowship . Current status: General surgery resident, NY Hospital.

° Julia Charles, M.D., Ph.D. (2000-2001) Postdoctoral Student/Fellow. Current status: Assistant Professor of Medicine, UCSF School of Medicine

° Sharon Benzeno (2000-2003), Graduate Student ; Current status: Scientific Liaison, Astra Zeneca Pharmaceuticals

° Steven Yea (2002-2008). Medical Student, then MSTP Student Awardee: Howard Hughes Med Inst. Medical Student Research Fellowship (2002); AASLD Student Research Prize (2004)

° Shlomit Goldberg (2002-2004). Summer research medical student. Inductee AOA, Current status: Radiology resident, Massachusetts General Hospital.

° Eldad Hod (2002- 2003). Summer research medical student. Inductee AOA, Current status: Asst Professor of Pathology, Columbia P&S.

° George Cheng (2002 - ) Medical Student, then MSTP Student; Awardee: ALF Student Summer Research Fellowship

° Rakhi Garg (2003-4). Undergraduate research student. Awardee: AGA Student Research Award

° Aline Wong (2003). Summer research medical student. Awardee: Chinese American Medical Society Scholarship.

° Xiao Zhao (2004). Summer research medical student. Awardee: AGA Student Research Award (2004); AASLD Student Research Prize, (2006). Howard Hughes Medical Inst. Student Research Fellowship (2005). Current status: Medical Chief Resident, Yale U School of Medicine

Scott L. Friedman

8

° Karina Arbatova (2004-2005). Medical student one-year research trainee Awardee: Doris Duke Student Research Fellowship.

° Andrew Paris (2005-2008 ). Summer research medical student, then Doris Duke Foundation Fellow. Awardee: AOA and Doris Duke Foundation Student Research Fellowships.

° Ursula Lang (2006- ). MSTP Student. ° Zahra Ghiassi-Nejad (2007- ). MSTP Student ° Jingjing Jiao (2008- ). PhD Student ° Yedidya Saiman (2008- ). MSTP Student ° David Zhang (2010- ). MSTP Student ° Ori Rackovsky (2010- ). MSTP Student Awardee: Howard Hughes Medical Institute

Student Research Fellowship. Postdoctoral fellows and Visiting scientists: ° Don C. Rockey, M.D. (1989-92). UCSF Gastroenterology Research Fellow. Awardee,

AGA Research Fellow Supplement & NIH National Research Service Award. Current status: Professor and Chief of Digestive Diseases, UT Southwestern.

° Paul Winwood, M.D (1994-95). Visiting fellow from Southampton University School of Medicine, UK. Awardee, ALF Research Fellow Supplement. Current status: Senior Lecturer, Southampton Univ., UK.

° Vlad Ratziu, M.D. (1994-96), Visiting fellow from Faculte de Medicine Paris-Sud, France, Awardee: ALF Research Fellow Supplement and Squibb Research Fellow Award. Current status: Professor of Medicine , Faculte de Medicine Paris-Sud.

° Victor Ankoma-Sey, M.D. (1994-96). UCSF Gastroenterology Research Fellow. Awardee: AGA Research Fellow Supplement, Individual NIH Natl. Res. Service Award & American Digestive Health Foundation Awards.

Current status: Asst. Prof of Medicine, U. of Houston Medical Center. ° Dan Li, M.D. (1998-2003), Postdoctoral Fellow. Awardee: American Liver Foundation,

Postdoctoral fellow grant and ALF Fellowship Research Prize, AASLD Meeting 2000. Current status: Internal medicine resident, Brigham & Women’s hospital, Harvard U.

° Elvira Olaso-Montero, Ph.D. (1998- 2001), Postdoctoral Fellow. Current status: Associate Professor, Universidad del pais vasco . Awardee: Ramon y Cajal Spanish Ministry of Science & Technology 5 year grant.

° Kazuo Ikeda, M.D., Ph.D. (1999- 2001), Postdoctoral Fellow. Awardee: ALF Postdoctoral Research Fellowship. Current status: Associate Professor, Osaka City U. School of Medicine.

° Efsevia Albanis, M.D. (1999-2001), Postdoctoral Fellow, Awardee: Amgen/AASLD Liver Scholar award (2001); Mount Sinai Wasserman Award (2003), Am Liver Foundation Sherlock Translational Research Award (2004); Current status: Project leader, Pharmasset Pharmaceuticals.

° Lieming Xu, M.D., PhD. (1999-2001), Postdoctoral Fellow. Current status: Professor and Lab Director, Shanghai Institute of Traditional Chinese Medicine.

° Hiroaki Iwamoto, M.D. (2000-2001 ), Postdoctoral Fellow. Current status: Assistant Professor, Kyushu School of Medicine.

° Helen Reeves, M.D., Ph.D. (2000-2003 ) Postdoctoral Fellow. Awardee: Glaxo Smith

Scott L. Friedman

9

Kline Senior Fellowship, UK, 2003-2008. Current status: Faculty, Northern Cancer Center and University of Newcastle School of Medicine.

° Sigal Tal-Kremer, M.D. (2001-2002 & 2004- ), Postdoctoral Fellow. ° Alex Hui, M.D., (2001-2002) Postdoctoral fellow; Awardee: Silver medal in the 2002

Best Dissertation Award by the Hong Kong College of Physicians. Current status: Assistant Prof. of Medicine. Prince of Wales Hosp. and Chinese U. of Hong Kong

° Michael Cooreman, M.D. (2001- 2003) Postdoctoral fellow. Current status: Associate Medical Director, Clinical Affairs, Novartis Pharmaceuticals

° Peter Olinga, Ph.D. (2001 - 2002) Postdoctoral fellow. Current status: Senior postdoctoral fellow, U. of Gronigen, Netherlands

° Nobuyuki Matsumoto, M.D. (2001 - 2006) Postdoctoral fellow. Current status: Assistant Professor Mariana University Hospital, Tokyo.

° Rifaat Safadi, M.D. (2001-2002). Visiting scientist. Current status: Faculty Hebrew University School of Medicine, Jerusalem.

° Prof. Michael JP Arthur, M.D. (2002-2003). Awardee: Senior Fulbright Distinguished Fellow and Visiting Professor. Current status: Vice-Chancellor, Leeds University, UK. (equivalent to University President).

° Kunihara Akita, M.D., Ph.D (2002-2004) Postdoctoral fellow. Current status: Asst Professor, Gifu U. School of Medicine

° Michaela Banck, M.D. (2002-2004). Postdoctoral fellow. Awardee: Charles Revson Fellowship & American Society of Clinical Oncology Clinical Scholar Award. Current status: Asst Professor of Medicine, Hematology Oncology Division, Mount Sinai

° Brian Radbill, M.D. (2002- 2005). Former postdoctoral fellow from Nephrology Division. Awardee: NIH NRSA Grant. Current status: Asst. Professor of Medicine, Mount Sinai School of Medicine

° Josep Llovet, M.D. (2003 - 2004). Visiting faculty from U. Barcelona. Current status: Associate Professor of Medicine, Mount Sinai School of Medicine and Research Professor, U. of Barcelona (joint appointment)

° Ying Bei Chan, M.D., PhD. (2004- 2005). Postdoctoral fellow. ° Samara Ginzburg, M.D. (2004 – 2005). Postdoctoral fellow. ° Efrat Broide, M.D. (2005). Visiting scientist from Israel.

° Yongchul Kim M.D. (2006 - 2007). Visiting scientist from Korea. ° Jinsheng Guo M.D., PhD. (2006-2008). Visiting scientist from Fudan University, China. Current status, Associate Professor, Fudan U. Shanghai ° Mirko Tarocchi M.D. (2006-2009). Postdoctoral fellow. Current status, Assistant Professor, U Firenze ° Wladimiro Jimenez, PhD. (2006-2007). Visiting scientist from Barcelona Clinic, Spain. ° Augusto Villaneuva M.D. (2005-2008). Postdoctoral fellow. Current status: Assistant Professor, U. of Barcelona ° Beatriz Minguez M.D. (2007-2009). Postdoctoral fellow. Current status: Assistant

Professor, U. of Barcelona ° Rebekka Hannivoort, M.D. (2008- ). Postdoctoral fellow from Groningen U, Holland. ° Lars Bechmann, M.D. (2008- ). Postdoctoral fellow from U Essen Germany. ° Ursula Munoz, Ph.D. (2009- ). Postdoctoral fellow from U Madrid, Spain. Recipient, Fundación Alfonso Martín Escudero fellowship

Scott L. Friedman

10

° Virginia Hernandez-Gea, M.D. (2009- ). Postdoctoral fellow from U Barcelona, Spain. ° Michal Cohen M.D. (2009- ). Postdoctoral fellow from Sheba Medical Center, Israel. Recipient, Davidoff Research Fellowship. ° Tatiana dePaula, Ph.D. (2009-2010). Postdoctoral fellow from U Rio de Janeiro, Brazil ° Young-Min Lee, M.D. (2009- ). Postdoctoral fellow from U Heidelberg, Germany. Recipient, DFG Research Fellowship ° Peri Kocabayoglu, M.D. (2010- ). Postdoctoral fellow from U Essen Germany. ° Juan Enrique Puche M.D. , Ph.D. (2010- ). Postdoctoral fellow from U Madrid, Spain. Recipient, Fundación Alfonso Martín Escudero fellowship ° Juan Antonio Suarez Cuenca M.D., Ph.D. (2010- ). Postdoctoral fellow from UNAM,

Mexico City, Mexico.

Selected Invited Lectures and Visiting Professorships (1989 - present):

1989 American College of Gastroenterology Annual Meeting, New Orleans, LA, "AIDS and the

Gastrointestinal Tract - Current Therapy Update". Visiting Physician, University of Buffalo Medical Center, "Mechanisms of hepatic fibrosis"

and "Gastrointestinal manifestations of AIDS". 1990 American College of Physicians Annual Meeting, Special Presentation, New Orleans, LA.

"Hepatobiliary manifestations of AIDS. American College of Gastroenterology Annual Postgraduate Course, Boston, "Management

of diarrhea and malnutrition in AIDS". 1991 University of Texas Southwestern School of Medicine, GI Division Basic Science Course,

Dallas, "How hepatic injury leads to hepatic fibrosis and cirrhosis". Falk Symposium on Liver Fibrogenesis, Marburg, Germany, "Molecular interactions

between Kupffer cells and lipocytes". 1992 UCSF Dean's Research Seminar, "From insult to injury - mechanisms of hepatic fibrosis". European Tissue Repair Society Annual Meeting, Malmo, Sweden, "Macrophage-

mesenchymal cell interactions in hepatic fibrosis". Beth Israel Hospital Seminar in Medicine, Harvard Medical School, Boston, MA. "Hepatic

fibrosis - Cellular mechanisms and evolving therapeutic strategies". UCSF Medical Grand Rounds, "A binge too far - mechanisms and therapeutic strategies for

Scott L. Friedman

11

alcoholic liver disease" AASLD Annual Postgraduate Course, Chicago, IL. "Hepatic fibrogenesis in alcoholic liver

disease" 1993 Falk Symposium on "Fat-storing cells and Liver Fibrosis", Florence, Italy. "Gene expression

during lipocyte activation" Am. Soc. for Pharm. and Exp. Therapeutics, SF,CA; Symposium on "Role of ECM in wound

healing", "Mechanisms of lipocyte activation and role of ECM in liver injury" European Assn. for the Study of Liver (EASL), Symposium on "Cytokines and the liver",

Paris, "The network of cytokines and growth factors in liver fibrogenesis"

1994 Falk Symposium on "Cytokines and the liver", Freiburg, Germany Weizmann Institute of Science Seminar, "Molecular mechanisms of mesenchymal cell

activation in hepatic wound healing", Rehovot, Israel. University of Southern California GI Division Seminar, “Cellular and Molecular

mechanisms of hepatic wound healing". American College of Gastroenterology Postgraduate Course,"Abdominal pain syndromes in

AIDS", San Francisco, CA. Gastroenterological Society of Australia, Symposium on "Cell biology of the extracellular

matrix in gastrointestinal and liver diseases", Sydney Harvard Medical School Postgraduate Course on Basic Science for Clinicians - "Healing and

fibrosis as a cause of disease", Boston, MA. AASLD Annual Meeting, Workshop on "Hepatic Fibrosis", Moderator 1995 (sabbatical) Falk Symposium on Molecular Biology of Liver Disease, "Molecular fibrogenesis” , Basel,

Switzerland. Bancroft Silver Jubilee Symposium, Queensland Institute of Medical Research, "Molecular

mechanisms of hepatic fibrogenesis", Brisbane, Australia. Medical Grand Rounds, Hadassah Medical Center, Soroka Medical Center, Carmel Hospital,

Israel, “Mechanisms of liver fibrosis and prospects for therapy”. 1996

Scott L. Friedman

12

Gordon Conference on effects of ethanol on cell metabolism and injury, "Stellate cell activation and fibrogenesis", Oxnard, CA.

Swedish National Conference on mechanisms of liver injury and fibrosis, Molecular

mechanisms of liver fibrosis", Gothenburg, Sweden. Japan Digestive Disease Week Workshop Keynote Speaker "Hepatic fibrosis and prospects

for treatment", Kobe, Japan. Royal Free Hospital Liver Update, "Molecular Mechanisms of hepatic fibrosis and prospects

for therapy", London, UK Gastroenterology Research Group Scientific Symposium on Proinflammatory Cytokines in

GI and Liver Disease, “Cytokines and liver fibrosis”, Chicago, IL AASLD Annual Meeting, Early morning workshop on “Matrix turnover in hepatic fibrosis”,

Chicago, IL. 1997 European Assn. for the Study of the Liver, Symposium on Hepatic Fibrosis, “Transcriptional

regulation in liver fibrosis”, London, UK. AGA Postgraduate Course, “Will chronic liver disease be a medically curable?”

Washington, DC . International Symposium on Hepatology, “Molecular mechanisms of hepatic fibrosis”,

Beijing, China. AASLD Postgraduate Course, “Role of stellate cells in fibrosis and blood flow regulation”,

Chicago, IL. 1998 New York Society of Gastroenterology, “Molecular mechanisms of fibrosis and prospects

for therapy”. Massachusetts General Hospital GI Grand Rounds and Research Conference, “Molecular

mechanisms of hepatic fibrosis” and “Transcriptional and signaling events in hepatic stellate cell activation”.

NIAAA Workshop on “Alcohol and Hepatitis C”, “Molecular regulation of stellate cell

activation: implications for defining therapeutic targets in hepatic fibrosis” FASEB Summer Research Conf. on Mechanisms of Liver Growth and Differentiation in

Health and Disease, “Molecular mechanisms of hepatic fibrogenesis”, Snowmass, CO.

Scott L. Friedman

13

ISBRA 98 Congress Symposium on Pathogenesis of Alcohol-related Liver Disease,

“Mechanisms of alcoholic fibrogenesis”, Copenhagen, Denmark. World Congress of Gastroenterology, “Update on hepatic fibrosis”, Vienna, Austria . Falk Symposium on Diseases of the Liver and Bile Ducts, “Fibrosis and bile duct injury”,

Prague, Czech Republic. Mount Sinai Med School, ‘Mini-med school’, “Liver disease and hepatitis” Visiting Professor, University of Pennsylvania Gastroenterology Division. GI Research Seminar, Yale University School of Medicine, “Molecular regulation of hepatic

wound healing”. American Liver Foundation Irwin Arias M.D. Symposium on “Bridging Basic Science and

Liver Diseases”, “Stellate cells: biology and pathobiology”, Boston, MA. NIH Conference on “Emerging issues in infectious diseases - Hepatitis C”, “Evaluation of

fibrosis in Hepatitis C”, Bethesda MD.

1999 Featured Speaker, Minophagen Symposium on “Stellate cells and Fibrosis”, “Molecular

mechanisms of liver fibrosis and prospects for therapy”, Tokyo, Japan. Medical Grand Rounds, Gifu and Osaka City Universities, “Mechanisms of hepatic

fibrosis”, Japan. Visit supported by a Japan Industry, Science and Technology Travel Grant.

Hepatitis Foundation International’ National Hepatitis Congress, “Fibrosis and indicators of

progression in HCV”, Washington, D.C. Mount Sinai School of Medicine, Alumni Day, 20th Reunion Class Speaker, “Sinai, stellate

cells, and cirrhosis - past, present and future.” Visiting Professor, University of Iowa Gastroenterology Division. Basel Liver Week, Symposium on Liver Cirrhosis and its Development, “Liver

fibrogenesis”, Basel, Switzerland. Osler Interurban Clinical Club, “Molecular regulation of hepatic fibrosis and emerging

prospects for therapy”, New York, NY. Society of Gastroenterology Nurses and Associates, “Pathogenesis and therapies of hepatic

fibrosis”, Dallas, TX

Scott L. Friedman

14

AASLD Postgraduate Course, “Hepatic fibrosis - past, present and future”, Dallas, TX. University of North Carolina, Gastroenterology Division Seminar, “Molecular mechanisms

of hepatic fibrosis and emerging prospects for therapy", Chapel Hill, NC. Visiting Professor, Gastroenterology Division, Brown University School of Medicine Charles Flood Memorial Lecture, NY Presbyterian Hospital, Weill Medical College GI

Postgraduate course, “Mechanisms of hepatic fibrosis and prospects for therapy”. 2000 Falk Symposium on Chronic Hepatitis, Cologne, Germany, “Mechanisms of hepatic

fibrosis”. Visiting Professor, Mayo Medical School Gastroenterology Division. Medical Grand Rounds, New York University School of Medicine. Belgian Society for Cell Biology, Brussels, “The hepatic stellate cell – myofibroblast

transition – role of transcription factors” National Hepatitis Foundation, Washington DC. “Update in treatment of hepatic fibrosis” Tisdale Invited Professor, University of Vermont School of Medicine. Research Seminar, Dept of Molecular Cell Biology, Weizmann Inst of Science, Israel, "Novel

paradigms in growth regulation and fibrosis signaling - lessons from the liver". AASLD Single Topic Conference on Hepatic Fibrosis. "Transcriptional regulation of

hepatic fibrosis", Airlie, Virginia

Postgraduate Course, International Assn for the Study of the Liver, "Progress in hepatic fibrosis", Fukuoka, Japan

Japan Society of Hepatology, Keynote Speaker, “Molecular regulation of liver fibrosis”,

Fukuoka, Japan. International Symposium on Development, Fibrosis and Transformation of the Pancreas,

"Molecular regulation of hepatic stellate cell activation - a paradigm for pancreas?", Ulm, Germany

Visiting Professor, Hannover School of Medicine, "Molecular mechanisms of hepatic

fibrosis", Hannover, Germany

Scott L. Friedman

15

FASEB conference on liver growth and development, "Non-parenchymal cells and liver growth", Snowmass, CO.

AASLD Single Topic Conference on Biliary Tract Diseases, "Biliary fibrosis", Atlanta, GA Ernst Hafter State of the Art Lecture, Swiss Gastroenterological Assn., “Hepatic fibrosis:

pathophysiologic basis and potential for pharmacotherapy” Mount Sinai School of Medicine Dean’s Lecture, “Novel paradigms of growth regulation

and signaling - lessons from the liver” Research Seminar, Albert Einstein College of Medicine Liver Center Visiting Professor, University of Pittsburgh School of Medicine Harvard Medical School ‘Think Tank” on Systems and Molecular Mechanisms of Liver

Cirrhosis, “Clinical and molecular aspects of liver fibrosis” Medical Grand Rounds, University of Texas at Houston School of Medicine, “Mechanisms

of liver fibrosis and prospects for therapy”

2001 Visiting Professor, UCSF School of Medicine Gastroenterology Division Visiting Professor, Washington U. School of Medicine, Gastroenterology Division Rockefeller U. Hepatitis C Center Seminar, “Novel mechanisms of growth regulation and

signaling in liver” International Conference on New Strategies for the Treatment of Liver Cirrhosis, “Molecular

mechanisms of stellate cell activation and ECM accumulation”, Tokyo, Japan.

Invited lecturer, Jikei University and Juntendo University Schools of Medicine, “Novel pathways of growth regulation and signaling in liver”, Japan.

AASLD Single Topic Conference on New Therapeutic Strategies for Hepatitis C, Fibrosis

session chair, Chicago, IL. Visiting Professor, Hadassah Medical Center Liver Unit, Hebrew University, Jerusalem. Fred Hutchinson Cancer Research Center, Clinical Sciences Lectureship Program,

“Molecular regulation of hepatic stellate cells: implications for liver toxicity from chemotherapeutic drugs”, Seattle, WA

Jacobsen Lecturer and Visiting Professor, University of Newcastle School of Medicine, United Kingdom.

Scott L. Friedman

16

Invited lecturer, Gronigen University, Dept of Pharmacology, Gronigen, Netherlands. AASLD Single Topic Conference on Veno-occlusive disease, “Hepatic fibrosis”, Atlanta,

GA Falk Symposium on Cytokines in Liver Injury and Repair,”Stellate cell activation by

cytokines”, Hannover, Germany. Invited lecturer, University of Upssala Dept of Biology, “Novel signaling mechanisms in

liver fibrosis”, Upssala, Sweden. AASLD Annual Postgraduate Course, “Antifibrotic therapy in cirrhosis”, Dallas TX.

European Assn. for the Study of Liver Single Topic Conference on Liver Fibrosis: from Cell

Biology to Clinical Targets, “Molecular mechanisms of stellate cell activation”, Florence , Italy.

Third International Hepatology Symposium, “Intercellular interactions in the development

of liver fibrosis”, Hangzhou, China. American College of Rheumatology Symposium on Gene Expression Profiling in Organ

Fibrosis, “Hepatic Fibrosis”, San Francisco, CA. Instituto Nacional de ciencias medicas y nutricion, Symposium on Emerging Concepts in

Inflammation and Fibrogenesis, “Future prospects for the treatment of liver and pancreatic fibrosis”, Villahermosa, Mexico.

2002 Visiting Professor, Gastroenterology Division, UCLA School of Medicine. Urology Grand Rounds, UCSF. “KLF6, a novel tumor suppressor in prostate cancer”, San

Francisco, CA University of Texas Symposium on Hepatic Inflammation and Immunity, “Mechanisms of

stellate cell activation and the role of lymphocytes”, Galveston, TX. UNC Chapel Hill Conference on Fibrogenesis and Inflammation in Liver and Intestine,

“Molecular regulation of hepatic stellate cell activation”, Chapel Hill, NC. King’s College Paediatric Hepatology Update, “Mechanisms of hepatic fibrosis”, London

UK. BMC Lecture Series on Molecular and Cellular Biology, Uppsala U., “Novel pathways of

tumor suppression and ECM signaling – lessons from liver”, Uppsala, Sweden.

Scott L. Friedman

17

University of Toronto Update on Liver Disease and IBD – issues and controversies. “New

aspects of treatment of hepatic fibrosis”, Paradise Is., Bahamas. State-of-the-Art Lecture, American Gastroenterological Association Annual Meeting,

“Molecular mechanisms of hepatic fibrosis”, San Francisco, CA. Ninth International HCV meeting, “Hepatic fibrosis in HCV infection”, San Diego, CA. FASEB conference on liver growth and development, "Hepatic fibrosis- advances",

Snowmass, CO. Ninth International Sinusoidal Cell Symposium invited lecture. “Immune regulation of

hepatic fibrosis”, Tucson, AZ. Visiting Professor, Rochester General Hospital, “The new frontier; Diagnosis and

treatment of hepatic fibrosis”. Basic Science Symposium, Dutch Society of Hepatology 25th Anniversary meeting, “New

insights in mechanisms of hepatic fibrosis”, Eindhoven, Netherlands. Medical Grand Rounds, NYU VA Medical Center, “Hepatic fibrosis” Medical Grand Rounds, U. of Massachusetts Medical Center, “Hepatic fibrosis, emerging

principles of diagnosis and therapy” Worcester ,MA. Watson Memorial Lecture, University of Minnesota School of Medicine, “Hepatic fibrosis,

the new frontier”. Minneapolis, MN.

2003 Medical Grand Rounds, Weill Cornell School of Medicine, “Hepatic fibrosis” Medical Grand Rounds, Columbia P&S School of Medicine, “Hepatic fibrosis” Mount Sinai Hospital 150th Anniversary Symposium, “KLF6, a novel tumor suppressor gene

in multiple cancers” Rockefeller University, Clinical Scholars Program, “Novel pathways in growth regulation

and signaling – lessons from the liver” American Gastroenterological Assn. Annual Meeting, Clinical Symposium – “Pathogenesis

of cirrhosis”, Orlando, FL Vanderbilt University School of Medicine Gastroenterology Division, Seminar – “KLF6, a

tumor suppressor gene in human cancer” Nashville, TN

Scott L. Friedman

18

Clinical Care Options, Symposium - “Immunopathogenesis of fibrosis”, Laguna Niguel, CA.

Duke University Liver Disease Update - “Understanding fibrosis and therapies”, Raleigh –

Durham, NC. U. Pennsylvania Liver Update – “Hepatic fibrosis”, Philadelphia, PA 5th International Meeting on Therapy of Liver Diseases, “Molecular regulation of stellate cell

activation”, Barcelona, Spain. Royal College of Physicians Update in Liver Disease Treatments, “Prospects for treatment

of Liver Fibrosis”, London, UK. Falk Liver Symposium – “Hans Popper Award - Acceptance Speech” and “Molecular

regulation of fibrosis”, Freiburg, Germany. 2004 Visiting Professor – Gastroenterology Division, St Louis University School of Medicine Visiting Professor – U. Massachusetts Medical Center GI Division, Worcester, MA. BIO CEO & Investor Conference – “Liver Disease – The new frontier in biotech”, NY, NY Visiting Professor – Beth Israel Deaconess Medical Center Liver Section, Boston, MA. Axcan Symposium on ‘Portal hypertension in the 21st century’ – “Mechanism of hepatic

fibrogenesis”, Montreal, Canada. American Society of Investigative Pathology Annual Meeting – “Molecular mechanisms of

hepatic stellate cell activation and extracellular matrix production”, Bethesda, MD.

U. Tennessee Symposium on ‘Pathogenic mechanisms in fibrosis – search for common

ground’. “Vascular origin of hepatic myofibroblasts” AGA Clinical Symposium on Prognostic Markers in Liver Disease: “Prognosticating the

future: genomics and beyond”. New Orleans, LA. FASEB Conference on Liver Development, Differentiation and Disease: “KLF6, a novel

tumor suppressor gene regulating differentiation and fibrosis”, Snowmass, CO. Visiting Professor, University of Washington Hepatitis C Center: “Hepatic fibrosis, the new

frontier in liver disease”. Seattle, WA.

Scott L. Friedman

19

Invited speaker, International Symposium on Cells of the Hepatic Sinusoid: “Alternative splicing of the KLF6 tumor suppressor during hepatic stellate cell activation is a a fibrogenic signal”. Bilbao, Spain.

Scientific Co-organizer & Speaker, Falk International Symposium on Injury and Repair in

Liver and Pancreas: “View of hepatology” , Freiburg, Germany.

2005 First Joint Israeli-American Gastroenterological Assns. Meeting, “Hepatic fibrosis, the new

frontier in liver disease”, Dead Sea, Israel. Duke U. Symposium on Fibrosis as endpoint for Clinical Trials in Liver Disease:

“Mechanisms of Fibrosis – Have we worked it all out?”, Tyson’s Corner, Virginia. AASLD Single Topic Conference on HCV: “Strategies to stabilize liver injury”, Chicago,

IL. BIO-CEO & Investor Conference, “Hepatitis: the Silent Killer”, New York, NY. University of Miami Hepatology Postgraduate Course, “Newer insights on the pathogenesis

of hepatic necroinflammation and fibrosis& targets for therapy”, Bar Harbour, FLA. Visiting Professor, University of Rochester Gastroenterology Division, Rochester, NY. Hack Lecturer and Visiting Professor, Stanford U. Gastroenterology Division, Palo Alto,

CA.

John Carbone Visiting Professor, UCSF Gastroenterology Division, San Francisco , CA. NIDDK Workshop on Fibrosis Imaging, “Molecular Structure and Pathophysiology of

Liver Fibrosis”, Bethesda, MD. Visiting Professor, University of Michigan Gastroenterology Division, Ann Arbor MI.

Research Society on Alcoholism NIAAA Satellite Symposium on Mechanisms of Alcohol- Induced Fibrosis, “Alcoholic Liver Fibrosis – Evolving Concepts and Future Directions”, Santa Barbara, CA. Brookhaven National Laboratory, “Hepatic fibrosis – problems and prospects for novel approaches to diagnosis”, Brookhaven, NY. Florida Society of Gastroenterology, “Liver biopsy – status and pitfalls in clinical practice”, Naples, FL.

Scott L. Friedman

20

7th International Symposium on Cytokines and Chemokines, “Fibrosis, cytokines and hepatitis”, Montreal, Canada. First Intl. Symposium on Liver Diseases with Chinese Integrative Medicine, “Hepatic fibrosis”, Shanghai, China. Montefiore Medical Center Medical Grand Rounds, “Hepatic fibrosis, the new frontier in liver disease”, Bronx, NY.

Armed Forces Medical College and Vellore Medical College Symposia, “Hepatic fibrosis - mechanisms and treatment approaches,” Pune and Vellore, India.

2006 Visiting Faculty, 5th Annual U. of Zurich Gastrointestinal and Hepatobiliary Research Retreat, Vulpera, Switzerland. Atkinson Lecture / Medical Grand Rounds, Northwestern U School of Medicine, “Hepatic fibrosis, the new frontier in liver disease”, Chicago, IL. Featured Speaker, Retirement Ceremony of Prof. Isao Okazaki, “Recent update in molecular

mechanisms of stellate cell activation and hepatic fibrosis”, Tokyo , Japan. Gastroenterology Grand Rounds, Medical College of Virginia. “Mechanisms of progression

of liver fibrosis to cirrhosis”, Richmond VA 11th International GEMHEP Meeting, “How does fat trigger fibrogenesis?”, Paris, France. International Association of the Study of the Liver, Hans Popper Lecture, “Reversal of

hepatic fibrosis, fact or fantasy?”, Cairo, Egypt. American Pancreatic Association State of the Art Lecture. “Stellate cells and fibrosis”,

Chicago, IL. Turkish National Gastroenterology Congress, “Hepatic Fibrosis Direct and Indirect

Markers, Pathophysiology and Antifibrotic Therapies” Istanbul, Turkey. Indian and Asian-Pacific Associations for the Study of Liver, Joint Single Topic Conference

on Hepatic Fibrosis: Basic Science to Therapies, Kolkata, India. 2007 Visiting Professor, Fudan University and Hongzhao Hospital, Hepatology 2007, “Challenges

and Opportunities”, Shanghai, China Featured Speaker , Choshu Liver Symposium, “Hepatic fibrosis update”, Yamaguchi,

Japan.

Scott L. Friedman

21

Zetzel Visiting Professor in Gastroenterology, Beth Israel Deaconess Hospital, Boston MA. Keynote Speaker, Keystone Symposium on Molecular Mechanisms of Fibrosis,

“Fibrogenic cells in tissue repair – sources features and implications”, Tahoe, CA.

Workshop on Reversal of Liver Fibrosis: Evidence-based medicine? “Liver fibrosis – from mechanisms to treatment”, Bordeaux, France.

Ninth Intl. Worskhop on Adverse Reactions and Lipodystrophy in HIV. Liver fibrosis in

HIV. Sydney, Australia. Falk Foundation, Hepatic Fibrosis Symposium, University of Cologne, Germany. AGA/BSG Joint Symposium on Inflammation, Repair and Fibrosis. “Stellate cells in liver

fibrosis”, London, UK. 7th International Meeting on Therapy in Liver Diseases, “Effect of antiviral therapy on

fibrosis”, Barcelona, Spain. Falk Symposium on Liver Cirrhosis: from Pathophysiology to Disease Management.

“Hepatic fibrogenesis and carcinogenesis: Krüppel like factors and beyond”, Dresden, Germany.

NIH Workshop on Nuclear Receptors in Liver. “Molecular mechanism of hepatic fibrosis

and the role of nuclear receptors”, Bethesda, MD. AASLD Career Development Workshop. “Effective mentoring – the senior faculty

perspective”, Boston, MA. Mexican Society of Gastroenterology Postgraduate Course – Bridging Basic and Clinical

Sciences, “Hepatic Fibrosis”, Leon, Mexico. 2008 AASLD Future Trends Conference, “The structure of a Hepatology Division”, Alexandria,

VA Pittsburgh Gut Club, “Hepatic Fibrosis- the New Frontier”, Pittsburgh PA

University of Texas Symposium on Hepatic Inflammation and Immunity, “Stellate cell

Interactions with T cells, Dendritic Cells and Fibrosis”, Galveston, TX. First Intl Symposium on Kruppel Like Factors, (Co-Organizer), “KLF6: Emerging Roles in

Liver Cancer, Development & Injury”, Tokyo, Japan. Falk Symposium on Chronic Inflammation of the GI Tract and Liver, “Can we stop

Scott L. Friedman

22

progression of liver fibrogenesis?”, Honzhao, China. Special Symposium, Cho-Ray Hospital, “Mechanisms and treatment of hepatic fibrosis’,

Ho Chi Minh City, Vietnam.

British Society of Toxicology, “Liver fibrosis, an overview”, Surrey, UK. Trinity College - Seminar. “Immune interactions and stellate cells”, Dublin. European Assn for the Study of Liver, Special Symposium, “Pathogenesis of HCC, the fibrosis connection”, Milan, Italy. DeGraff Memorial Lecturer, Research Day, NYU School of Medicine, “Hepatic fibrosis – personalized and promising”, New York NY. EASL Monothematic Conf. on Liver Cancer, “Fibrogenesis and HCC”, Prague, Czech Republic. Am. Assn of Pharmaceutical Sciences, “Targeting antifibrotics to liver”, Toronto, Canada U. of Mexico, Zubiran Institute Postgraduate Course, “¿Es reversible la fibrosis

hepatica?” &“Fibroscan, fibrotest y otros: ¿son útiles en la práctica clínica?”, Mexico DF. 3rd Intl. Symposium on alcoholic liver disease and cirrhosis, “Emerging concepts in hepatic fibrosis – the confluence of genetics and molecular biology”, Bilbao, Spain.

Dean’s Distinguished Lecture, Georgetown School of Medicine, “From fibrosis to cancer and back, the story of the KLF6 Tumor suppressor”, Georgetown, DC. Turkish National Gastroenterology Assn, State of the Art Lecture, “Molecular mechanisms

of hepatic fibrosis”, Adana Turkey. 2009 EASL Single Topic Conference on Portal Hypertension, “Hepatic fibrogenesis”, Budapest,

Hungary. Keystone Conference on Organ Fibrosis, “Genetic regulation of fibrosis”, Keystone, CO. Asian-Pacific Assn for the Study of Liver State of the Art Lecture “Emerging concepts in

hepatic fibrosis”, Hong Kong, China Klatskin Memorial Lecture, Yale University School of Medicine, “From fibrosis to cancer

and back, the story of the KLF6 Tumor suppressor”, New Haven, CT American Society for Investigative Pathology Fibrosis Symposium, “Emerging mechanisms

Scott L. Friedman

23

and evolving strategies for hepatic fibrosis”, New Orleans, LA. Institute for Advanced Studies, Governor’s Symposium, “From fibrosis to cancer and back,

the story of the KLF6 Tumor suppressor”, Princeton, NJ. American College of Veterinary Internal Medicine, “Hepatic fibrosis – mechanisms,

diagnosis and therapeutic challenges”, Montreal, Canada.

Intl Liver Cancer Assn, “Fibrogenesis and HCC”, Milan, Italy Keynote lecture, Intl. HCV meeting "Pathogenesis of liver fibrosis in chronic hepatitis C",

Nice, France United European Gastroenterology Week, “Antifibrotic therapy, clinical endpoints”, London UK Rafael Research Alumni Visiting Scientist, "Hepatic fibrosis – an emerging translational

paradigm” Rambam Hospital, Haifa University, Israel 2010 Invited speaker, U. of Zurich Liver Research Retreat, “Genetic mechanisms of progression

risk in hepatic fibrosis”, Vulpera, Switzerland Keynote Lecture, Dutch Society of Experimental GI and Hepatology, “Molecular

mechanisms of hepatic fibrosis”, Veldhoven, Netherlands Sheila Sherlock Honorary Lecture, British Society of Gastroenterology, “Molecular

mechanisms and clinical challenges in hepatic fibrosis”, Liverpool, UK. GI Grand Rounds and Cancer Center Seminar, U Wisconsin. “Hepatic fibrosis” and “Role

of KLF6 in hepatocellular carcinoma”, Madison, WI. Medical Grand Rounds (Englert Lecture) and Huntsman Cancer Center, U Utah. “Hepatic

fibrosis, the new frontier”, and “Inflammation, Fibrosis and HCC”, Salt Lake City. Keynote Lecturer, Cuban Assn for the Study of Liver, “Molecular mechanisms of hepatic

fibrosis and prospects for therapy”, Havana, Cuba. Invited lecturer and Co-organizer, FASEB Conference on Kruppel like factors – Biology and

Pathobiology, “KLF6 – roles in development and cancer”, Steamboat Springs, CO. Invited lecturer, FASEB Conference on Liver Biology and Development, “ A novel

paradigm of stellate cell activation” , Snowmass, CO.

Keynote Lecturer, Intl Society for Hepatic Sinusoid Research “ Evolving mysteries of the hepatic stellate cell” , Pasadena, CA.

Scott L. Friedman

24

Keynote Lecturer, 8th Australasian Conference on Viral Hepatitis, “Mechanisms of fibrosis in viral hepatitis” and “Prospects for therapy of hepatic fibrosis, Melbourne, Australia. Invited Lecturer, Czech Hepatology Society, “Update on hepatic fibrosis”, Prague, Czech. Invited Lecturer, No. American Cystic Fibrosis Conference, “Mechanisms of hepatic fibrosis in cystic fibrosis liver disease”, Baltimore, MD. Invited Lecturer, 20th Annual Irwin Arias American Liver Foundation Symposium, “New paradigms in hepatic fibrosis”, Boston, MA Current Support: 1. S. Friedman, PI. "The role of KLF6 in hepatocellular carcinoma." NIH #1 RO1 DK37340-19. Award dates: July 1, 2004 - June 30, 2008. Total direct costs, $1,000,000 (exact amt pending). 2. S. Friedman, PI, “The role of KLF6 in hepatic fibrosis”. NIH #DK56621-06. Award dates: October 1, 2005 - September 30, 2009. Direct costs, $1,230,515. 3. S. Friedman & S. Itzkowitz, co-PIs. Training program in gastroenterology and hepatology. NIDDK, T32 DK 07792-01. Award dates: December 1, 2000 - November 30, 2004, Direct costs, $998,

4. S. Friedman. PI. NIAAA, 1 P20 AA017067-01. Oxidant Stress and Fibrosis in Alcoholic Liver Injury. Total funding period: September 1, 2008 to August 31, 2013. Total direct costs $1, 474, 930 requested (final award amount pending)

Pharmaceutical and Biotechnology Consulting 1999 - 2001 Schering Plough Corporation, Kenilworth, NJ. 1999- 2003 Millennium Pharmaceutials, Cambridge, MA. 1999- 2001 Quark Biotechnology Inc., Ness Ziona, Israel.

2000- 2003 Bayer-Chiron Diagnostics, Emeryville, CA. 2000- 2005 Pfizer Pharmaceuticals, UK

2000- 2002 Zymogenetics, Seattle WA. 2001- 2003 Geron Corporation, Redwood City, CA

2001- 2005 Wyeth-Ayerst, Pearl River, NY 2002-2005 Maxim Pharmaceuticals, San Diego, CA 2003-2004 Prometheus, Inc., San Diego CA 2004- 2005 Eli Lilly Pharmaceuticals, Indianopolis, IN

2003- 2004 Metabasis Pharmaceuticals, San Diego, CA 2003- 2005 Idun Pharmaceuticals, San Diego, CA 2005- 2006 Gilead Pharmaceuticals, Foster City, CA

Scott L. Friedman

25

2002- Celera Diagnostics, Alameda, CA 2003- Genzyme Pharmaceuticals, Cambridge, MA 2003- Novartis Pharmaceuticals, East Hanover, NJ 2004 Aventis Pharmaceuticals, Bridgewater, NJ 2004- Intercept Pharmaceuticals 2005- Glaxo Smith Kline, Research Triangle Park, NC 2005- Biogen Idec, Boston, MA 2007 Conatus Pharmaceuticals, CA 2007- Pro-pharmaceuticals, MA 2007- Exalenz Diagnostics, Israel 2008- Synvista Pharmaceuticals, NJ 2008- Pfizer Pharmaceuticals, NY

United States Patents

US Patent no. 6,264,949 B1. Noninvasive agents for diagnosis and prognosis of the progression of fibrosis. Inventor: Scott L. Friedman. Date of patent : July 24, 2001. US Patent no. US2005/ 0181374 KLF6, a novel growth inhibitory and tumor suppressor gene. Inventors: Scott L. Friedman, D. Li G. Narla, JA Martignetti, KE Heath. US Patent pending. Use of gleevec in treatment of hepatic fibrosis. Inventors: Scott L. Friedman, M.D. and Efsevia Albanis MD. US Patent pending. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased cancer risk. Inventors: John A. Martignetti, M.D., PhD, Goutham Narla and Scott L. Friedman, M.D.

US Patent pending. A 3 gene signature to predict hepatocellular carcinoma. Inventors: Josep Llovet, M.D., Scott L. Friedman M.D., and Myron Schwartz, M.D. US Patent pending. Glatiramer acetate for use as an immuno-modulatory agent to treat hepatic fibrosis Inventors: Rifaat Safadi, M.D., and Scott L. Friedman M.D.

Scott L. Friedman

26

Publications: Peer-Reviewed Papers Wall S, Friedman SL and Margulis A. Gastrointestinal Kaposi's Sarcoma in AIDS: radiographic manifestations. Journal of Clinical Gastroenterology 6:165-171, 1984. Friedman SL, Wright TL and Altman D. Gastrointestinal Kaposi's Sarcoma in patients with Acquired Immunodeficiency Syndrome: endoscopic and autopsy findings. Gastroenterology 89:102-108, 1985. Friedman SL, Roll FJ, Boyles J and Bissell DM. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proceedings of the National Academy of Sciences, 82:8681-8685, l985. Friedman SL and Roll FJ. Isolation of hepatic lipocytes, Kupffer cells and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Analytical Biochemistry, 161:207-218, 1987. Maher JJ, Friedman SL, Roll FJ and Bissell DM. Immunolocalization of laminin in normal rat liver and biosynthesis of laminin by hepatic lipocytes in primary culture. Gastroenterology, 94:1053-1062, 1988. Maher JJ, Bissell DM, Friedman SL and Roll FJ. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. Journal of Clinical Investigation, 82:450-459,1988. Arenson DM, Friedman SL and Bissell DM. Formation of extracellular matrix in normal liver: lipocytes as major source of proteoglycans. Gastroenterology 95:441-447, 1988. Friedman SL, Roll FJ, Arenson DM, Boyles JS, and Bissell DM. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. Journal of Biological Chemistry, 264:10756-10762, 1989. Arthur MJP, Friedman SL, Roll FJ and Bissell DM. Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane collagen. Journal of Clinical Investigation, 84:1075-1086, 1989. Friedman SL and Arthur MJP. Activation of rat hepatic lipocytes by Kupffer cell-conditioned medium (KCM): direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of PDGF receptors. Journal of Clinical Investigation, 84:1750-1754, 1989. Friedman G, Friedman SL and Boyles J. Apolipoprotein E is secreted by cultured lipocytes of the rat liver. Journal of Lipid Research, 32:107-114, 1991. Friedman SL, McGuire RF, Boyles JS, Maher JJ, Rockey DC and Yamasaki G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphologic and functional characteristics in

Scott L. Friedman

27

primary culture. Hepatology, 15:234-243, 1992. Rockey DC, Boyles JS, Gabbiani G and Friedman SL. Rat hepatic lipocytes express alpha smooth muscle actin upon activation in culture and in vivo. Journal of Submicroscopic Cytology and Pathology, 24:193-203, 1992. Iredale JP, Murphy G, Hembry RM, Friedman SL and Arthur MJP. Human hepatic lipocytes synthesize and release TIMP-1, an important regulator of matrix metalloproteinase activity. Journal of Clinical Investigation, 90:282-287, 1992. Rockey DC, Maher JJ, Jarnagin W, Gabbiani G and Friedman SL. Inhibition of rat hepatic lipocyte activation in culture by interferon gamma. Hepatology, 16:776-784, 1992. Arthur MJP, Stanley A, Iredale JP, Murphy G, Hembry RM, and Friedman SL. Secretion of 72 kD type IV collagenase/gelatinase by cultured human lipocytes; analysis of gene expression, protein synthesis, and proteinase activity. Biochemical Journal, 287: 701-707, 1992. Friedman SL, Wei S and Blaner WS. Retinol release by activated rat hepatic lipocytes - regulation by Kupffer cell conditioned medium and PDGF. American Journal of Physiology, 264:947-952, 1993. Rockey DC, Housset CN, and Friedman SL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. Journal of Clinical Investigation, 92:1795-1804, 1993. Lee SJ, Friedman SL, Whalen R, and Boyer TD. Cellular sources of glutathione S-transferase pi in primary cultured rat hepatocytes and lipocytes: localization by in situ hybridization. Biochemical Journal, 299:79-83, 1994. Friedman SL, Yamasaki G, and Wong LS. Modulation of TGFß receptors in rat hepatic lipocytes during the hepatic wound healing response; enhanced binding but reduced gene expression accompany cellular activation in culture and in vivo. Journal of Biological Chemistry, 269:10551-10558, 1994. Wong LS, Yamasaki G, Johnson RJ and Friedman SL. Induction of ßPDGF receptor in rat hepatic lipocytes during cellular activation in vivo and in culture, Journal of Clinical Investigation 94:1563-1569, 1994. Shankland S, Pippin J, Pichler RH, Gordon KL, Friedman SL, Gold LI, Johnson RJ Couser WG. Differential expression of transforming growth factor β isoforms and receptors in experimental membranous nephropathy. Kidney International 50:116-124, 1996. Ankoma-Sey V ,Tzagarakis C, Chang KB, Friedman SL. Downregulation of matrix and ß-PDGF receptor gene expression by anti TGFß antibody in rat hepatic stellate cells during experimental liver injury. International Hepatology Communications, 6:144-152, 1997. Friedman SL, Shaulian E, Littlewood T, Reznitzsky D and Oren M. Resistance to p53-mediated

Scott L. Friedman

28

growth arrest and apoptosis in Hep 3B hepatoma cells, Oncogene, 15:63-70, 1997. Lalazar A, Burd S, Wong L, and Friedman SL. Early gene induction in hepatic stellate cells during the wound healing response. Gene, 195 (2): 235-243, 1997. Agani F, Kirsch DG, Friedman SL, Kastan MB and Semenza GL. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Research, 57(20):4474-7, 1997. Ankoma-Sey V, Chang KB, Lalazar A, Donner DB, Wong L, Warren RS, Friedman SL. Coordinated induction of VEGF receptors in mesenchymal cell types during wound healing. Oncogene, 17 (1): 115-121, 1998. Ratziu V, Lalazar A, Wong L, Dang Q, Collins C, Shaulian E, Jensen S, and Friedman, SL. Zf9, a Kruppel-like transcription factor upregulated in vivo during hepatic stellate cell activation. Proceedings of the National Academy of Sciences, USA, 95:9500-9505, 1998. Kim Y, Ratziu V, Choi S-G, Lalazar A, Theiss G, Dang Q, Kim SJ, and Friedman SL. Transcriptional Activation of TGF-β1 and its receptors by the Kruppel-like factor Zf9/CPBP and Sp1; potential mechanisms for autocrine fibrogenesis in response to injury. Journal of Biological Chemistry, 273: 33750-33758, 1998. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Scaffidi CA, Friedman SL, Galle PR, Stremmel W, Oren M and Krammer PH. The CD95 (APO-1/Fas) is a DNA-damage-inducible p53 regulated death receptor gene. Journal of Experimental Medicine, 188 (11):2033-45, 1998. Okuno M, Sato T, KitamotoT, Imai S, Nagase S , Suzuki Y, Yoshimuri H, Moriwaki H, Masushige S, Muto Y, Friedman SL, Kato S, and Kojima S. Increased 9,13-di-cis-Retinoic Acid in Rat Hepatic Fibrosis: A Potential link between retinoid loss and TGF-β mediated fibrogenesis via RARα activation. Journal of Hepatology, 30:1073-1080. 1999. Whalen R, Rockey DC, Friedman SL, and Boyer TD. Activation of rat hepatic stellate cells leads to loss of glutathione S transferases and enzymatic activity against products of oxidative stress. Hepatology, 30:927-933, 1999. Nieto N, Friedman SL, Greenwel P and Cederbaum A. CYP 2E1 mediated oxidative stress stimulates collagen gene expression in rat hepatic stellate cells. Hepatology, 30:987-996, 1999. Kojima S, Hayashi S, Suzuki Y, Shimada J, Crippa MP, and Friedman SL. Transcriptional activation of urokinase-type plasminogen activator by the Krüppel-like factor Zf9/COPEB activates latent TGF-ß1 in vascular endothelial cells. Blood, 95(4):1309-16, 2000. Okano J, Opitz OG, Nakagawa N, Jenkins TJ, Friedman SL and Rustgi AK. The effects of the Krüppel-like transcriptional factors Zf9 and GKLF on the human keratin 4 promoter and evidence of direct interaction. FEBS Letters, 473:95-100, 2000.

Scott L. Friedman

29

Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, and Blaner WS. Retinoid processing and CRBP actions, and regulation by nuclear retinoid receptors in a rat hepatic stellate cell line. Journal of Lipid Research, 41(6):882-93, 2000. Nieto N, Greenwel P, Friedman SL, Zhang F, Dannenberg AJ, and Cederbaum AI. Ethanol and arachidonic acid increase α2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1: role of H202 and cyclooxygenase-2. Journal of Biological Chemistry, 275(26):20136-45, 2000. Mitnick JA, Grey A, Masiukiweicz U, Rios-Velez, L, Friedman SL, Xu L, Horowitz MC, Insogna K. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. American Journal of Physiology, 280(3):E405-E412, 2001. Shimizu M, Hara A, Okuno M, Matsuno H, Okada K, Ueshima S, Matsuo O, Niwa M, Akita K, Yamada Y, Yoshimi N, Uematsu T, Kojima S, Friedman SL, Moriwaki H and Mori H. Mechanism of retarded liver regeneration in plasminogen activator deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic necrosis. Hepatology, 33: 569-176, 2001. Takehara T, Liu X, Fujimoto J, Friedman SL, and Takahashi H. Inhibition of apoptosis by Bcl-xL expressed in human hepatocellular carcinoma cells. Hepatology, 34(1):55-6, 2001. Laub F, Aldabe R, Ramirez F, and Friedman SL. Embryonic expression of Kruppel-like factor 6 in neural and non-neural tissues. Mechanisms of Development, 106(1-2):167-7, 2001. Matsushima-Nishiwaki R, Okuno M, Sano T, Akita K, Adachi S, Moriwaki H, Friedman SL and Kojima S. Phosphorylation of retinoid X receptor α impairs its metabolism in human hepatocellular carcinoma. Cancer Research, 61:7675-7682, 2001.

Olaso E, Ikeda K, Eng F, Xu L, Wang L, Lin HC, Yancopoulos G, and Friedman SL. DDR2 receptor promotes MMP-2 mediated proliferation and invasion of hepatic stellate cells during liver injury. Journal of Clinical Investigation, 108: 1369-78, 2001.

Narla G, Heath K, Reeves H, Li D, Giono LE, , Narla J, Glucksman M, Kimmelman A, Eng FJ, Chan A, Ferrari A, Martignetti J and Friedman SL. Kruppel-like factor 6, a candidate tumor suppressor gene mutated in prostate cancer. Science, 294:2563-5, 2001. (in the top 1% of citations in its field according to the Essential Science IndicatorsSM )

Nieto N, Friedman SL, and Cederbaum AI. Stimulation and proliferation of primary hepatic stellate cells by cytochrome p450 2E1-derived reactive oxygen species. Hepatology, 35:62-73, 2002. Adachi A, Okuno M, Matsushima-Nishiwaki R, Kojima S, Friedman SL, Moriwaki M, and Okano Y. Phosphorylation of retinoid X receptor at serine 260 suppresses its ubiquitin/proteasome-mediated degradation in human hepatocellular carcinoma. Hepatology, 35:332-340, 2002.

Scott L. Friedman

30

Olaso E, Labrador P, Wang L, Ikeda K, Eng F, Klein R, Lovett DH, Lin HC, and Friedman SL. DDR2 receptor regulates fibroblast proliferation and invasion by transcriptional activation of MMP-2. Journal of Biological Chemistry, 277: 3606-3613, 2002. Nieto N, Friedman SL, and Cederbaum A. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. Journal of Biological Chemistry, 277: 9853-9864, 2002. Saxena N, Ikeda K, Rockey DC, Friedman SL, and Anania FA. Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 35(4): 762-771, 2002 Ikeda K, Wang LH, Torres R, Zhao H, Olaso E, Eng FJ, Yancopoulos GD, Friedman SL, and Lin HC. Discoidin Domain Receptor 2 (DDR2) interacts with Src and Shc following its activation by type I collagen . Journal of Biological Chemistry, 277(21):19206-12, 2002. Botella LM, Sánchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada S, Guerrero-Esteo M, Cooreman MP, Ratziu V, LangaC, Vary CPH, Ramírez JR, Friedman SL and Bernabéu C. Transcriptional activation of endoglin and TGFbeta signaling components by cooperative interaction between Sp1 and KLF6; their potential role in the response to vascular injury. Blood, 100:4001-4010, 2002. Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, Yasuda I, Yamada Y, Akita K, Sano T, Shimada J, Kojima S, Okano Y, Friedman SL and Moriwaki H. Synergistic induction of apoptosis by acyclic retinoid and interferon-β in human hepatocellular carcinoma cells . Hepatology 36:1115-1124, 2002. Mao TK, Kimura Y, Kenny TP, Branch A, Temkin S, Gish R, Van De Water J, Friedman S, Gershwin ME. Elevated expression of tyrosine kinase DDR2 in primary biliary cirrhosis. Autoimmunity, 35(8): 521-529, 2002. Taimr P, Higuchi H, Kocova E, Rippe R, Friedman SL, and Gores G. Activated human stellate cells express the TRAIL receptor-2/Death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology, 37(1):87-95, 2003. Olaso E, Salado C, Eguiledor E, Gutierrez V, Santisteban A, Friedman SL and Vidal-Vanaclocha F. Proangiogenic role of tumor- activated hepatic stellate cells in experimental melanoma metastasis Hepatology, 37(3):674-685, 2003. Taimr P, Torok N, Higuchi H, Friedman SL and Gores G. Apoptotic body engulfment by human stellate cells is profibrogenic . Laboratory Investigation, 83(5):655-663, 2003. Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis, 24(8):1353-1359, 2003.

Scott L. Friedman

31

Takano Y, Adachi S, Okuno M, Muto Y, Yoshioka T, Matsushima-Nishiwaki R, Tsurumi H, Ito K, Friedman SL, Moriwaki H, Kojima S, and Okano Y. The RING-Finger Protein, RNF8, interacts with retinoid X receptor a and enhances its transcription-stimulating activity. Journal of Biological Chemistry, 279:18926-18934, 2004. Reeves HL, Narla G, Ogunbiyi O, Haque A, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJP, Martignetti JA, Friedman SL. Kruppel like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in colorectal cancer. Gastroenterology,126:1090-1103, 2004. Benzeno B, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS,. Odin JA, Diehl JA, Germain G, Friedman SL. Cyclin dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Research, 64(11): 3885-91, 2004. Kimmelman A, Qiao RF, Narla G, Bos P, Sanfiz A, Lau N, Li D, Eng FJ, Liang BC, Guha A, Martignetti JA, Friedman SL and Chan AML. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor, KLF6. Oncogene, 23:5077-83, 2004. Rubinstein M, Idelman G, R Plymate SR, Narla G, Friedman SL, and Werner H. Transcriptional activation of the IGF-I receptor gene by the KLF6 tumor suppressor: potential interactions between KLF6 and p53. Endocrinology, 145(8): 3769-77, 2004. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, and Friedman SL. Immune stimulation of hepatic fibrosis by CD8 T cells and its attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology, 127:870-882, 2004. Hui AY, AJ Dannenberg AJ, Sung JJY, Subbaramaiah K, Du B, Olinga P, and Friedman SL Prostaglandin E2 inhibits transforming growth factor β1-mediated induction of collagen α1(I) in hepatic stellate cells. J Hepatology, 41: 251-258, 2004. Wang X, Tang X, Gong X, Albanis E, Friedman SL, and Mao M. Regulation of hepatic stellate cell activation and growth by MEF2. Gastroenterology, 127:1174-1188, 2004. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage B, Martignetti JA, Friedman SL. Frequent inactivation of the tumor suppressor Kruppel like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 40:1047-1052, 2004. Wandzioch E, Kolterud A, Jacobsson M, Friedman SL and Carlsson L. Lhx2-/- mice develop liver fibrosis. Proceedings of the National Academy of Sciences, USA, 101 (47): 16549-16554, 2004. Tang S, Bhatia B, Zhou J, Maldonado CJ, Chandra D, Kim E, Fischer SM, Butler AP, Friedman SL, Tang DG. Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene, 23(41): 6942-53, 2004

Scott L. Friedman

32

Xu L, Hui AY, Albanis E, Arthur MJP, Friedman SL and Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2, new tools for elucidating mechanisms of fibrogenesis. Gut, 54:142-151, 2005. Narla G, DiFeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod H, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng L, Chang B-L, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research, 65(4):1213-1222, 2005. Bansal MB, Kovalovich K, Lib W, Cilberto G, Friedman SL, and Taub RA. Interleukin-6 attenuates acute toxin-induced liver injury and apoptosis in mice by reducing matrix metalloproteinase-2. Journal of Hepatology, 42(4):548-56, 2005. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, Suzuki R, Kohno H, Matsushima-Nishiwaki R, Takano Y, Tsurumi H, Kojima S, Friedman SL, Moriwaki H, Tanaka T. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer, 51(2):197-206, 2005. van de Bovenkamp M, Groothuis GMM, Draaisma AL, Merema MT, Bezuijen JI, van Gils MJ, Meijer DKF, Friedman SL, and Olinga P. Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicological Sciences, 85(1): 632-8, 2005. Lee JS, Decker NK, Chatterjee S, Yao Y, Friedman SL, and Shah V. Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. American Journal of Pathology, 166(6):1861-70, 2005. Narla G, Difeo A, Yao S, Banno A, Hod E, Reeves H, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL*, and Martignetti JA* (*shared senior authorship). Targeted inhibition of the KLF6 splice variant KLF6SV1 suppresses prostate cancer growth and spread. Cancer Research, 65(13): 5761-5768, 2005. Li D, Yea S, Cooreman MP, Li S, Narla G, Laborda J Banck M, Friedman SL (corresponding author) and Walsh MJ. KLF6 promotes preadipocyte differentiation through histone deacetylase 3 (HDAC3)-dependent repression of Dlk1 . Journal of Biological Chemistry, 280(29): 26941-52, 2005. Safadi R, Alvarez CE, Ohta M, Brimnes J, Kraus T, Mehal W, Bromberg J, Mayer L and Friedman SL. Enhanced oral tolerance in transgenic mice with hepatocyte secretion of interleukin-10. Journal of Immunology, 175(6):3577-83, 2005. Li D, Yea S, Dolios D, Martignetti JA, Narla G, Wang R, Walsh MJ and Friedman SL. Regulation of Krüppel-like factor 6 tumor suppressor activity by acetylation. Cancer Research, 65(20):9216-9225, 2005.

Scott L. Friedman

33

Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL, Ikeda K. BMP-7 Opposes TGFβ1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. American Journal of Physiology, 290(1):L120-6, 2006. Kirschenbaum A, Liu X-H, Yao S, Narla G, Friedman SL and Levine AC. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral vs. transition zones, Carcinogenesis, 27(2):216-24, 2006. Matsumoto N, Kubo A, Liu H, Akita K, Laub F, Ramirez F, Keller G, and Friedman SL. Developmental regulation of yolk-sac hematopoiesis by Krüppel-like Factor 6. Blood, 107 (4), 1357-1365, 2006. Melhem A, Mohanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Asadi A, Nassar M, Friedman SL and Safadi R. Anti-fibrotic Activity of NK cells in experimental liver injury through killing of activated HSC. Journal of Hepatology, 45(1): 60-71, 2006. Zhan S-S, Wu J, Halsted C, Friedman SL, Zern MA, and Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology, 43(3):435-443, 2006 Huang H, Shiffman M, Cheung RC, Friedman SL, Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, Catanese JJ, Leong DU, Ross D, Hu X, Emerson R, Monto A, McAllister LB, Broder S, White TW, Sninsky JJ, Wright, TL. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology, 130(6):1679-87, 2006 Basu, Saito K, Meyer K, Ray RB, Friedman SL, Chang Y-H, and Ray R. Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes. Apoptosis, 11(8):1391-400, 2006. DiFeo A, Narla G, Hirschfeld J, Camacho-Vanegas O, Yao S, Rose SL, Kalir T, Friedman SL, Buller RE and Martignetti JA. KLF6 allelic loss and increased alternative splicing are frequent events defining ovarian cancer progression and metastatic spread. Clinical Cancer Research, 12(12): 3730-9, 2006. DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ and Martignetti JA. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene, 25 (44): 6026-6031, 2006. Chan ESL, Montesinos MC , Fernandez P , Desai A, Delano DL, Yee H, Allison AB, Pillinger MH, Chen J-F, Schwarzschild MA, Friedman SL & Cronstein BN. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. British Journal of Pharmacology, 148:1144-115, 2006. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SM, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV-cirrhosis.

Scott L. Friedman

34

Gastroenterology, 131(6):1758-1767, 2006. Mori M, Fushimi N, Asano T, Maruyama T, Ohashi K, Okumura S, Inoue H, Takekoshi S, Friedman SL and Okuno M. Cardiovascular tolerance in unsedated upper endoscopy: a prospective randomized comparison between transnasal and conventional procedures. Digestive Endoscopy, 18(4): 282-287, 2006. Horani A, Muhanna N, Pappo O, Melhem A, Alvarez CE, Doron S, Wehbi W, Friedman SL and Safadi R. The beneficial effect of glatiramer acetate (Copaxone®) on immune modulation of experimental hepatic fibrosis. American Journal of Physiology, 292(2):G628-38, 2006. Kinoshita K, Iimuro Y, Fujimoto J, Inagaki Y, Namikawa K, Kiyama H, Nakajima Y, Otogawa K, Kawada N, Friedman SL, and Ikeda K. Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre-LoxP system to antagonize hepatic fibrosis. Gut, 56(3):396-404, 2006. Kremer-Tal, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee J-S, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA , Llovet JM, Friedman SL. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation in vivo. Journal of Hepatology, 46: 645–654, 2007. Kinoshita K, Iimuro Y, Otogawa K, Saika S, Inagaki Y, Nakajima Y, Kawada N, Fujimoto J, Friedman SL, Ikeda K. Adenovirus-mediated expression of BMP-7 suppresses the development of fibrosis in rats, Gut, 56(5):706-14, 2007. Wurmbach E, Chen Y, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel IM, Thung SN, Mazzaferro V, Bruix J, Bottinger E, Friedman SL, Waxman S Llovet JM. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma, Hepatology, 45(4):938-47,2007. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, Tarocchi M, and Friedman SL. In vivo regulation of p21 by the KLF6 tumor suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene, 26(30):4428-34, 2007. Teixeira MS, Camacho-Vanegas O Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Wang B, Friedman SL, Mark Urken M, Margaret Brandwein-Gensler M and Martignetti JA. KLF6 allelic loss is associated with tumor recurrence and poor survival in head and neck squamous cell carcinoma. International Journal of Cancer, 26(30):4428-34, 2007. Camacho-Vanegas O, Narla G, Teixeira MS, Difeo A, Misra A, Friedman SL Feuerstein B, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer, 121(6):1390-1395, 2007. Lee J, Belanger A, Douchette JT, Friedman SL, Stanca C, Bach N. Transplantation trends among Primary Biliary Cirrhosis patients from 1995 to 2004. Clinical Gastroenterology and Hepatology, 5(11):1313-5, 2007.

Scott L. Friedman

35

Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, Friedman SL, Carmeliet, P, Jimenez W, Morales-Ruiz MI. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology, 46(6):1919-26, 2007. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, and Jiménez W. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. Journal of Pharmacology & Exp. Therapeutics, 324(2):475-83, 2008. Higazi A, El-Haj M, Melhem A, Horani A, Pappo O, Alvarez C, Muhanna, N, Friedman SL, Safadi R. Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis. Clinical and Experimental Immunology, 152(1):163-7, 2008. Wang M, Guo JS, Tu CT, Wang JY, Friedman SL. A modified methodology for human hepatic stellate cell isolation. Fudan Univ J Med Sci, 35(4):617-620, 2008. Bentov I. Narla G, Schayek H, Akita K, Plymate SR. LeRoith D, Friedman SL and Werner H. Insulin-like growth factor-1 regulates KLF6 gene expression in a p53-dependent manner. Endocrinology, 149(4):1890-7, 2008 Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S , Hod H, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology, 134(5):1521-31, 2008. Miele L, Beale G, Patman G, Nobili V, Narla G, Friedman SL, Leathart J, Bugianesi E, Day CP, Reeves HL. The KLF6 genotype is associated with fibrosis in non-alcoholic fatty liver disease (NAFLD). Gastroenterology, 135:282-290, 2008. Muhanna N Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells following phagocytosis of lymphocytes – a novel pathway of hepatic fibrogenesis. Hepatology, 48(3): 963-977, 2008. Hoshida Y , Augusto A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression profiles of adjacent liver predict outcome in hepatocellular carcinoma. New England J Med, 359(19):1995-2004, 2008. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, Cozza LeBlanc A, Donovan DJ, Thung SN, Sole M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of vascular endothelial growth factor A and molecular classification of hepatocellular carcinoma. Cancer Research, 68(16): 6779-88, 2008.

Scott L. Friedman

36

Hartel M, Narla G, Wente MN, Nathalia A. Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL. Increased alternative splicing of the KLF6 tumor suppressor gene correlates with prognosis and tumor grade in patients with pancreatic cancer. European J Cancer, 44(13):1895-903, 2008. Narla G, Difeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest, 118(8): 2711-2721, 2008. Villanueva A, Chiang DY, Newell P, Peix J, Thung SN, Alsinet C, Roayaie S, Minguez B, Sole M, Battiston C, van Laarhoven S, Fiel IM, DiFeo A, Hoshida Y, Tovar V, Yea S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology, 135(6):1972-83, 2008. Jameel NM, Thirunavukkarasu C, Wu T, Watkins SC, Friedman SL and R. Gandhi CR. p38-MAPK- and caspase-3-mediated superoxide-induced apoptosis of rat hepatic stellate cells: reversal by retinoic acid. J Cell Physiol, 218(1):157-6, 2009. Bechmann LP, Zahn D, Gieseler RK, Fingas CD, Marquitan G, Jochum C, Gerken G, Friedman SL and Canbay A. Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells. Hepatology Research, 39:601-608, 2009. Mölleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M , Friedman SL, Tornøe I, Schlosser A, Klöppel G, Schmiegel W, Meyer HE, Holmskov U, Stühler, K. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology, 49(4):1257-66, 2009. Botella LM, Rodriguez-Sanz F, Komi Y, Fernandez A, Varela E, Garrido-Martin EM, Narla G, Friedman SL, and Soichi Kojima S. TGF-β regulates expression of KLF6 and its splice variants, and promotes cooperative transactivation of common target genes through a Smad3/Sp1/KLF6 interaction. Biochemical Journal, 419(2):485-95, 2009. Guo J, Loke J, Zheng F, Hong F, Yea S, Fugita M, Tarocchi M, Abar OT, Huang H, Sninsky JJ, Friedman SL. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4 to hepatic stellate cell responses. Hepatology, 49(3):960-8, 2009. Liu Y, Lui ELK, Friedman SL, Li L, Poon RT, Chen Y, Ye T, Wo J, Kok TW, Fan ST. PTK787/ZK22258 Attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling that converge on Akt. Laboratory Investigation, 89(2):209-21, 2009. Sangodkar J, Shi J, Difeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer, 45(4):666-76, 2009. Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, David Scholten D, Berres M-L, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E,

Scott L. Friedman

37

Gassler N, Friedman SL, and Trautwein C. Anti-fibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology, 137(1):309-19, 2009. Li Y, Chang M, Abar O, Garcia V, Rowland C, Catanese J, Ross D, Broder S, Shiffman M, Cheung

R, Wright T, Friedman SL, Sninsky J. Multiple variants in Toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatology, 51(4):750-7, 2009. Geetha S, Courtni E, Allen CE, Plum E, Friedman SL, Soejima K, Sauna ZE and Kimchi-Sarfaty C. Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry. Cytometry, 75(8):675-8, 2009. Liu Y, Wen XM, Lui ELK, Friedman SL, Ho NPS, Cui W, Li L, Ye T, Fan ST, and Zhang H. Therapeutic targeting of PDGF and TGFβ signaling pathway in hepatic stellate cells by PTK787/ZK22258. Laboratory Investigation, 89(10):1152-60, 2009. Hoshida Y, Nijman SMB, Kobayashi M, Chan JA, Brunet J-P, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, GolubTR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Research, 15;69(18):7385-92, 2009. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatology, 51(4):725-33, 2009. Tan HH, Fiel MI, Sun Q, Guo J, Gordon RE, Chen LC, Friedman SL, Odin JA, Allina J. Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. J Immunotoxicol. 6(4):266-75, 2009. Lee TF. Mak KM, Rackovsky O, Lin Y-L, Kwong AJ, Loke JC, and Friedman SL.. Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (adrp). J Cell Physiology, 223(3):648-57, 2010. Guo J, Feng F, Loke J, Yea S, Lim CL, Lee U, Mann D, Walsh M, Sninsky JJ, Friedman SL. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. Journal of Biological Chemistry, 285(8):5428-37, 2010. Lee UE, Ghiassi-Nejad Z, Paris A, Yea S, Narla G, Walsh W and Friedman SL. Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG oncogene. FEBS Letters, 584(5):1006-10, 2010. Huh SJ, Chen Y-L, Friedman SL, Huang H-JS, Cavenee WK, and Robertson G. KLF6 gene and early melanoma development in a collagen I-rich extracellular environment. J Natl Cancer Inst, 102: 1131-1147, 2010.

Scott L. Friedman

38

Shomron N, Hunt R, Hershko K, Pommier E, Geetha S, Blaisdell A, Marple A, Roma I, Jordan Newell J, Dobkin A, Allen C, Friedman SL, Hamasaki-Katagiri N and Kimchi-Sarfaty C. A splice variant of ADAMTS13 is expressed in human hepatic stellate cells and cancerous tissues. Thrombosis and Hemostasis, 104(3):531-5, 2010. Zhao X, Monson C, Gao C, Gouon-Evans V, Matsumoto N, Sadler-Edepli K*, Friedman SL*. Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells. Developmental Biology, 344(1):79-93, 2010 (*shared senior authorship). Garrido-Martín E, Vary C, Tarocchi M, Lee U, Friedman SL, Botella LM, Bernabéu C. Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Molecular Biology, Jun 29;11:51, 2010. Jiang JX, Venugopal S, Li Y, Scott F, Adamson R, Devaraj S, Gershwin ME, Friedman SL and Török NJ. NOX2 plays a key role in stellate cell activation and liver fibrogenesis, Gastroenterology, 139(4):1375-84, 2010. Tchirkov A, Sapin V, Marceau G, Chautard E, Narla G, Veronese L, Friedman SL, Khalil T, Vago P, KemenyJ-L, Verrelle P. Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem Lab Med 48:1167-1170, 2010. Muhanna N, Tair KA, Doron S, Amer J, Azzeh M, Mahamid M, Friedman SL, and Safadi R. Amelioration of hepatic fibrosis by NK cell activation. Gut, 2010, in press. Gieseler R, Marquitan G, Schlattjan J, Sowa, JP, Bechmann L, Timm J, Roggendorf M, Gerken G, Friedman SL, Canbay, A. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. Journal of Viral Hepatitis, 2010, in press. Radbill BD, Gupta R, Ramirez MCM, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB. Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression. Dig Dis Sci, 2010, in press. Dechêne A, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, Schlattjan M, Saner F, Baba HA, Paul A, Dries V, Odenthal M, Gerken G, Friedman SL, Canbay A. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. Hepatology 52(3):1008-1016, 2010. Hasegawa D, Fujii R, Yagishita N, Matsumoto N, Satoko A, Izumi T, Azakami K, Nakazawa M, Fujita H, Sato T, Araya N, Koike J, Tadokoro M, Suzuki N, Nagata N, Senoo H, Friedman SL, Nishioka K, Yamano Y, Itoh F, Nakajima T. E3 Ubiquitin ligase synoviolin is involved in liver fibrogenesis. PLoS One, in press, 2010. Marcos L, Alvarez C and Friedman SL. Mechanisms of liver fibrosis associated with experimental fasciola hepatica infection: roles of Fas2 proteinase and hepatic stellate cell Aactivation. Journal of Parasitology, in press, 2010.

Scott L. Friedman

39

Liu Y, Wang Z, Kwong SQ, Lik E, Lui H, Friedman SL, Li F, Lam RWC; Zhang GC, Zhang H, Ye T. Inhibition of PDGF, TGF-β and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatology, in press, 2011. Textbook Chapters, Reviews, and Editorials Friedman SL and Owen R. Chapter 65. AIDS and other sexually transmissable diseases, In Gastrointestinal Disease, Fourth Edition. Sleisenger MH and Fordtran JS, Editors. Philadelphia, PA: W.B. Saunders Co. 1989, pp 1242-1280. Friedman SL. Gastrointestinal and hepatobiliary neoplasms in AIDS. In "Gastrointestinal Manifestations of AIDS", Gastroenterology Clinics of North America, 17:465-486,1988. Friedman SL, Guest Editor. W.B. Saunders, Philadelphia, PA. Friedman SL. Gastrointestinal symptoms of AIDS. AIDS Clinical Care,1:17-20, 1989. Bissell DM, Friedman SL, Maher JJ and Roll FJ. Connective tissue biology and hepatic fibrosis, report of a conference. Hepatology, 11:488-498, 1990. Friedman SL. Cellular sources of collagen and regulation of collagen synthesis in liver. Seminars in liver disease, 10:20-29, 1990. Friedman SL and Bissell DM. Hepatic Fibrosis. Hospital Practice, 25:43-50, 1990. Friedman SL. "Acetaldehyde and alcoholic fibrogenesis - fuel to the fire but not the spark". Editorial. Hepatology, 12:609-612, 1990. Friedman SL. Kaposi's Sarcoma and Lymphoma of the Gut In AIDS. In "Gastroenterological Aspects of AIDS", Balliere's Clinical Gastroenterology. B. Gazzard, Editor. Balliere Tindall Publishers, London, 1990. Friedman SL. Neoplasms of the gastrointestinal tract and hepatobiliary system in acquired immunodefiency syndrome. Seminars in Gastroenterology, SL Friedman, Guest Editor; M. Sleisenger, Editor, W.B. Saunders, Philadelphia, PA, volume 1, number 2, 1991. Friedman SL. 'Cuts both ways' - collagenases, lipocyte activation and polyunsaturated lecithin. Editorial. Hepatology, 15:549-551, 1992. Friedman SL, Arthur MJP and Millward-Sadler. Cirrhosis and hepatic fibrosis. In Liver and Biliary Disease, third edition, R. Wright et al, editors, Balliere Tindall, London, pp. 822-881, 1992. Friedman SL. Methods of nonparenchymal liver cell isolation. In "In vitro biological systems: preparation and maintenance", CA Tyson and JM Frazier, editors, Methods in Toxicology, Academic Press, Orlando, FL, 1993, pp 292-310.

Scott L. Friedman

40

Rockey DC and Friedman SL. Cytoskeleton of hepatic lipocytes in normal and pathological conditions. Cell Motility and Cytoskeleton, 22:227-234, 1992. Maher JJ and Friedman SL. Parenchymal/non-parenchymal cell interactions in liver. Seminars in liver disease, 13:13-20, 1993. Friedman SL. Hepatobiliary infections in AIDS. In "Gastrointestinal and hepatic infections", C. Surawicz and R. Owen, editors, W.B. Saunders, Philadelphia, PA, 1993, pp 391-404. Friedman SL. The cellular basis of hepatic fibrosis - mechanisms and treatment strategies. New England Journal of Medicine, 328:1828-1835, 1993. Levenson S and Friedman SL. Infectious esophagitis. In "Current therapy of gastrointestinal disease". T. Bayless, editor. CV Mosby, St. Louis, 1994, pp. 48-52. Chan MF and Friedman SL. Gastritis and abdominal pain in HIV-infected patients. In "Infections of the gastrointestinal tract", MJ Blaser, PD Smith, JI Ravdin, HB Greenberg and RL Guerrant, editors. Raven Press, New York, NY, 1995. Maher JJ and Friedman SL. Pathogenesis of hepatic fibrosis, In Alcoholic Liver Disease (2nd ed); P. Hall, ed. Edward Arnold, Kent, UK, 1995. Housset CN, Rockey DC, Friedman SL and Bissell DM. Hepatic lipocytes: a major target for endothelin-1. J Hepatology 22: (2 suppl):55-60, 1995. Roll FJ and Friedman SL. The role of endothelial cells, Kupffer cells, lipocytes, and pit cells. In Liver and Biliary Diseases, second edition, N. Kaplowitz, Editor, Williams and Wilkins, Baltimore, MD, pp. 33-51, 1996. Friedman SL. Parenchymal Fe and collagen gene expression: an iron-clad association? Hepatology Elsewhere review, Hepatology 21: 1197-99, 1995. Friedman SL. Alcoholic liver disease. In Hepatology Up-to-date, a CD-ROM text. B. Rose and S.Chopra, editors. Up-to-date, Boston, MA., 1998. Friedman SL. Hepatic stellate cells. In Progress in liver disease. R. Ockner and J. Boyer, editors. WB Saunders, Philadelphia, PA. pp 788-796, 1996. Ratziu V and Friedman SL. Pathobiology of hepatic stellate cells. In Functional heterogeneity of the liver. F. Vidal-Vanaclocha, editor. RGLandes, Co. pp 133-160, 1997. Friedman SL. Molecular mechanisms of hepatic fibrogenesis. J.Gastroenterology 32:424-430, 1997. Friedman SL. Closing in on the signals of hepatic fibrosis (Editorial). Gastroenterology, 112:

Scott L. Friedman

41

1406-9, 1997. Friedman SL. Molecular mechanisms of hepatic fibrosis. Japan Pharmacology and Therapeutics, vol 24 Suppl 1, pp 1-3, 1996. Ankoma-Sey V. and Friedman SL. Hepatic stellate cells. In Liver growth and repair - from basic science to clinical practice. A. Strain and AM Diehl, editors. Eds. AJ Strain and AM Diehl. Chapter 20; pp512 - 537. Chapman and Hall, London, 1998. Friedman SL. Cellular networks in hepatic fibrosis. Digestion, 59: 368-371, 1998. Friedman SL. Hepatic Fibrosis. In Schiff’s Diseases of the Liver, 8th Ed., E. Schiff, W. Maddrey and M. Sorrell, editors. Raven press, Philadelphia, PA pp371-385, 1998. Friedman SL. Scarring in alcoholic liver disease - new insights and emerging therapies. Alcohol Health & Research World, 21:310-316, 1998. Olaso E and Friedman SL. Molecular mechanisms of hepatic fibrogenesis. Journal of Hepatology, 29:836-847, 1998. Friedman SL. Stellate cell activation in alcoholic fibrosis. Alcoholism: Clinical and Experimental Research, 23(5): 904-1, 1999. Friedman SL. Cytokines in fibrogenesis. Seminars in Liver Disease, 19(2): 129-140, 1999. Li D, and Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells - new insights and prospects for therapy. Journal of Gastroenterology and Hepatology, 14(7): 618-33, 1999. Koch J, Kim L, and Friedman SL. Chapter 5. Gastrointestinal aspects of AIDS. In San Francisco General Hospital AIDS Knowledgebase, 3rd edition. Cohen PT, Sande MA, Volberding P, et al, Editors. Lippincott, Williams &Wilkins, Philadelphia, PA, 1999. Friedman SL. The virtuosity of hepatic stellate cells (Editorial). Gastroenterology, 117:1244-6, 1999. Friedman SL. The evaluation of fibrosis in hepatitis C. American Journal of Medicine, 107(6B):27S-30S, 1999. Friedman SL. Molecular regulation o f hepatic fibrosis; an integrated cellular response to tissue injury (mini-review). Journal of Biological Chemistry, 275: 2247-2250, 2000. (cited 326 times through 2005 – in the top 1% of citations in its field according to the Essential Science IndicatorsSM ). Eng FJ and Friedman SL. New insights into hepatic stellate cell activation – the simple becomes complex. American Journal of Physiology, 279(1):G7-G11, 2000.

Scott L. Friedman

42

Berk PD, Min A and Friedman SL. Hepatology at Mount Sinai: the present and the future. Mount Sinai Journal of Medicine, 68(2):88-95, 2001. Friedman SL. Hepatic Fibrosis - Clinical Features, Mechanisms and Emerging Therapies. In Hepatology Up-to-date, a CD-ROM text. B. Rose, P. Bonis and S.Chopra, editors. Up-to-date, Boston, MA, 2000. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 32(6):1403-8, 2000. Albanis E and Friedman SL. Hepatic fibrosis; pathogenesis and principles of therapy. Clinics in Liver Disease, 5(2): 315-334, 2001. Bonis P, Friedman SL, Kaplan M. Is liver fibrosis reversible? Editorial. New England Journal of Medicine, 344(6):452-4, 2001. Okuno M, Adachi S, Akita K, Moriwaki H, Kojima S and Friedman SL. Liver fibrosis and hepatic stellate cells. Connective Tissue, 32(4):121-7, 2001. Friedman SL, Guest Editor. Forward: Hepatic stellate cells. Seminars in Liver Disease, 21(3):307-310, 2001. Eng F and Friedman SL. Transcriptional regulation in hepatic stellate cells. Seminars in Liver Disease, 21(3):385-395, 2001. Reeves H and Friedman SL. Activation of hepatic stellate cells – a key issue in liver fibrosis. Frontiers in Bioscience, 7: d808-26 2002. Crystal RG, Bitterman PB, Mossman B, Schwartz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR and Musson RA. Future research directions in idiopathic pulmonary fibrosis – summary of a National Heart Lung, and Blood Institute Working Group. American Journal of Respiratory and Critical Care Medicine, 166: 236-246, 2002. Albanis E and Friedman SL. Non-invasive markers of hepatic fibrosis. Clinical perspectives in GI. 5 (3): 182-187, 2002. Bansal M and Friedman SL. The enlarging role of matrix metalloproteinases in liver injury – beyond scar degradation - Commentary. Journal of Hepatology, Aug;37(2):293-4, 2002. Hui A and Friedman SL. Molecular basis of hepatic fibrosis. Expert reviews in molecular medicine, Cambridge Press, Cambridge UK. Vol. 5; 14 February 2003. http://www.expertreviews.org/03005684h.htm Bansal M and Friedman SL. Fibrogenesis. In, Encyclopedia of Gastroenterology. Gregory Gores and Leonard Johnson, Eds. Academic Press, San Diego, CA., 2003.

Scott L. Friedman

43

Li D and Friedman SL. Molecular mechanisms of stellate cell activation an dextracellular matrix remodeling in Extracellular matrix and the liver – approach to gene therapy. In Okazaki I, Ninomaya Y, Tanikawa K and Friedman SL, editors Elsevier Science Press, San Diego, CA. In press, 2003. Friedman SL and Arthur MJP. Reversing hepatic fibrosis. Science & Medicine 8 (2): 194-205, 2002. Friedman SL Grendell J, McQuaid K, Editors. Current Diagnosis and Treatment in Gastroenterology. Appleton & Lange, Norwalk, CT, 2002. Safadi R and Friedman SL. Hepatic fibrosis -- role of hepatic stellate cellactivation. MedGenMed (Medscape) 2002 Jul 15;4(3):27. Online at: http://www.medscape.com/viewarticle/436461. Friedman SL. Liver fibrosis – from bench to bedside. Journal of Hepatology, 38 Suppl 1:S38-53, 2003. Albanis E, Safadi R and Friedman SL. Treatment of hepatic fibrosis – almost there. Current Gastroenterology Reports, 2003;5(1):48-56. Narla G, Friedman SL and Martignetti JA. Krüppel cripples prostate cancer – KLF6 progress and prospects. Commentary. American Journal of Pathology, 162: 1047-1052, 2003. Canbay Al, Friedman SL and Gores GS. Apoptosis – The nexus of liver injury and fibrosis. Hepatology, 39:273-8, 2004. Friedman SL and Schiano TD. Cirrhosis of the Liver and Major Sequelae. In Cecil Textbook of Medicine, 20-22nd editions. J.C. Bennett and F. Plum, editors. WB Saunders, Philadelphia, PA, 2004 , pp 939-944 Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL & Moriwaki H. Retinoids in cancer chemoprevention. Current Cancer Drug Therapy, 4(3): 285-98, 2004. Friedman SL. The answer: Angiotensin II; The question: What do inflammation, oxidant stress, and fibrogenesis have in common? Commentary. J Hepatology, 40(6):1050-2, 2004. Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL, and Moriwaki H. Acyclic retinoid in the chemoprevention of liver cancer . Int J. Oncol, 24: 797-805, 2004. Friedman SL. Stellate cells: A moving target in hepatic fibrogenesis. Editorial. Hepatology, 40(5):1041-3, 2004. Friedman SL. Mechanisms of hepatic fibrosis and therapeutic implications. Nature Clinical Practice in Gastroenterology & Hepatology, 1(2): 98-105, 2004

Scott L. Friedman

44

Bansal MB and Friedman SL. Future treatments: Anti-fibrotic Agents, Nitric Oxide Donors, and Gene Therapy in the Treatment of Portal Hypertension. In Portal Hypertension: Pathobiology, Evaluation and Treatment. VH Shah and A Sanyal, eds. Humana Press Inc., Totowa, NJ. 2005, Friedman SL. Invited Commentary: Mac the knife? Macrophages, the double-edged sword of hepatic fibrosis. Journal of Clinical Investigation, 115(1): 29-32, 2005. Friedman SL, Co-editor. Liver Diseases: Biochemical Mechanisms & New Therapeutic Insights, S. Ali, DA Mann and SL Friedman, eds. Science publishers, Inc. Enfield, New Hampshire, 2006. Albanis E and FriedmanSL. Antifibrotic agents for liver disease. American Journal of Transplantation, 6:12-19, 2006. Friedman SL and Bansal MB. Reversal of hepatic fibrosis – fact or fantasy? (Invited review for 25th Anniversary issue). Hepatology, 43(S1):S82-S88, 2006. Friedman SL. Transcriptional regulation of hepatic stellate cell activation. Journal of Gastroenterology and Hepatology , 21 Suppl 3:S79-83, 2006. Lemmer E, Friedman SL and Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Seminars in Liver Disease, 26(4):373-84, 2006. Friedman SL, Rockey DC and Bissell DM. Hepatic fibrosis 2006: report of the third AASLD siingle topic conference. Hepatology, 45(1):242-249, 2006. Friedman SL. Reefer Madness? Assessing the effects of cannabinoids with a less jaundiced eye. Commentary. J Hepatology, 46(1):180-2, 2007. Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Seminars in Liver Disease, 27:55-76 2007. Mehal W and Friedman SL. The role of inflammation and immunity in the pathogenesis of liver fibrosis. In Liver Immunology, 2nd Edition, ME Gershwin, JM Veirling and MP Manns, eds. , pp 99-109, 2007. Friedman SL. Viewpoint. Reversibility of hepatic fibrosis and cirrhosis – is it all hype? Nature Clinical Practice in Gastroenterology and Hepatology, 4(5):236-7,2007. Guo JS and Friedman SL. Advances in clinical and translational studies of hepatic fibrosis and cirrhosis. In, Progress in the Therapy of Liver Diseases, V. Arroyo, editor, Ars Medica, 2007. Teixeira R, Marcos LA and Friedman SL. Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: new insights into antifibrotic therapy in hepatitis C. Hepatology Research, Aug;37(8):579-95, 2007.

Scott L. Friedman

45

Guo JS and Friedman SL. Hepatic fibrogenesis. Seminars in Liver Disease, 27(4):413-26, 2007. Friedman SL. News & Views: A deer in the floodlights: BAMBI meets hepatic fibrosis. Nature Medicine, 13(11):1281-2, 2007. Friedman SL. FIBROSE HEPATIQUE. Liver fibrosis: from mechanisms to treatment. Gastroenterol Clin Biol 31:812-814, 2007. Friedman SL. Hepatic stellate cells: protean, multifunctional and enigmatic cells of the liver. Physiological reviews 88:125-172, 2008. Friedman SL and Nieto N. Preview. Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors. Cell Metabolism, 7(3):187-8, 2008. Friedman SL. News & Views: Targeting siRNA to arrest fibrosis. Nature Biotechnology, 26(4):399-400, 2008. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatology, 48(5):858-79, 2008. Friedman SL. Mechanisms of hepatic fibrosis. Gastroenterology. 134(6):1655-69, 2008. Friedman SL. Hepatic fibrosis – Overview. Toxicology. 254(3):120-9, 2008. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2(6):803-16, 2008. Rustgi VK, Davis GL, Herrine SK, McCullough AJ, Friedman SL, Gores GJ. Future trends in hepatology: challenges and opportunities. Hepatology. 48(2):655-61, 2008. Friedman SL, McCullough A, Gores G. Commentary: Gastroenterology and hepatology: an evolving marriage, not an imminent divorce. Am J Gastroenterol. 104(1):10-1, 2009. Friedman SL. Extracellular matrix, In Signaling Pathways in Liver Diseases, 2nd Edition, JF Dufour and PA Clavien, Editors, SL Friedman, Associated Editor, Springer Verlag Publishers, Zurich, 2010, in press. Jiao J, Friedman SL and Aloman C. Hepatic Fibrosis. Current Opinion in Gastroenterology, 25(3):223-9, 2009. Narla G and Friedman SL. Kruppel-like factors and the liver. In Biology of Kruppel-like factors. R. Nagai, SL Friedman, M. Kasuga, Editors, Springer Verlag Publishers, Zurich, 2009, pp 141-150.

Scott L. Friedman

46

Friedman SL. Foreward to Clinical Hepatology; Principles and Practice of Hepatobiliary Diseases. H. Dancygier, Editor. Springer Verlag Press, Germany, 2010, page vii. Toffanin S, Friedman SL, Llovet JM. Preview - Obesity, inflammatory signaling and hepatocellular carcinoma – an enlarging link. Cancer Cell, 17:115-117, 2010. Garcia-Tsao G, Friedman SL, Iredale J , and Pinzani M. Now there are many (stages) where before there was one; in search of a pathophysiological classification of cirrhosis. Hepatology, 51(4): 1445-1459, 2010. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol, 7(8):425-3, 2010. Hernandez-Gea, V and Friedman SL. Mechanisms of hepatic fibrogenesis. Annual Review of Pathology, 2010, in press. Guo JS and Friedman SL.. Toll like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis and Tissue Repair, 2010, in press Lee YM and Friedman SL. Fibrosis in the Liver: Acute Protection and Chronic Disease. In Klaus H. Kaestner, editor: Progress in Molecular Biology and Translational Science, Vol. 97, Burlington: Academic Press, pp. 151-200, 2010. Bechman LP and Friedman SL. Fibrosis as a major mechanism of chronic liver disease. In Chronic liver failure: mechanisms and management. P. Ginès, P.S. Kamath, V. Arroyo, Editors. Humana Press, New York, NY, 2011, in press. Hernandez-Gea V and Friedman SL. Platelets arrive at the scene of fibrosis…..studies. Commentary, Journal of Hepatology, 2011, in press. Symposium Proceedings Friedman SL, Roll FJ and Bissell DM. Collagen phenotype of rat hepatic lipocytes in pure primary culture. In Cells of the Hepatic Sinusoid Volume 1, E. Wisse, R. Knook and K. Decker, editors, Kupffer Cell Foundation, Rijswijk, The Netherlands, pp. 255-256, 1986. Friedman SL. HIV-associated malignant lymphoma of the gastrointestinal tract. In AIDS in Gastroenterology and Hepatology, M. Classen and H. Dancygier, editors. Demeter Verlag Press, Munich, pp. 66-69, 1989. Friedman SL, Roll FJ and Bissell DM. Autocrine regulation of lipocyte matrix production: activation by extracellular matrix. In Cells of the Hepatic Sinusoid, Volume 2. E. Wisse, D.L. Knook and K. Decker, editors, Kupffer cell Foundation, pp. 61-63, 1989. Friedman SL. PDGF-dependent stimulation of rat hepatic lipocytes by human Kupffer cell medium.

Scott L. Friedman

47

In Cells of the Hepatic Sinusoid, Volume 3. E. Wisse, D.L. Knook, and R. McCuskey, editors, Kupffer cell Foundation, 1991, pp. 177-179. Friedman SL. The Molecular basis for Kupffer cell/lipocyte interactions. In Molecular and cell biology of liver fibrogenesis. A. Gressner & G. Ramadori, editors. Springer Verlag, 1992, pp. 385-392. Friedman SL. Induction of PDGF receptor during lipocyte activation. In Cells of the Hepatic Sinusoid, Volume 4. E. Wisse, D.L. Knook, and R. McCuskey, editors, Kupffer cell Foundation, 1993, p. 222-3. Friedman SL, Wong L, and Yamasaki G. Gene expression of cytokine receptors during lipocyte activation. In Fat storing cells and liver fibrosis. C. Surrenti, A. Casini, S. Milani, and M. Pinzani, editors. Kluwer Publishers. Dordrecht, Netherlands, 1994, pp.236-240. Friedman SL. Bile duct injury and fibrosis. In Biliary Diseases, P. Spicak, G Paumgartner , and J. Boyer, editors, Kluwer Publishers. Dordrecht, Netherlands, 1999, Symposium 107. pp 140-145. Friedman SL. Mechanisms of hepatic fibrogenesis. In Liver cirrhosis and its development. H. Blum, editor. Kluwer publishers. Dordrecht, Netherlands, 1999, Symposium 115, 1999. Friedman SL. Cellular sources of liver fibrosis. In Chronic hepatitis, new concepts of pathogenesis, diagnosis and treatment. P Schirmacher and HP Dienes, editors. Kluwer publishers. Kluwer publishers, Lancaster, UK, 2000. Friedman SL. Mechanisms of hepatic fibrogenesis. In Liver Cirrhosis and its Development. J. Boyer editor. Kluwer publishers, Lancaster, UK , 2002 . Olaso E, Ikeda K, Eng FJ, Xu L, Wang L, Lin HC, and Friedman SL. Role of DDR2 receptor in the activationof hepatic stellate cells. In, Cytokines in Liver Injury and Repair, Kluwer publishers, Lancaster, UK , 2002. Friedman SL. Hepatic fibrosis and carcinogenesis; KLF6 and beyond. Kluwer publishers, Lancaster, UK, 2008. Friedman SL. Is hepatic fibrosis reversible? In Gastroenterologia, Hepatologia y Endoscopia basadas en la evidencia. Editors, JKY Furusho, JFS Avila, EL Mendez, MU Esquivel. Fundacio Mexicana para la Salud, 2008. Friedman SL. Fibroscan, fibrotest and others. Are they clinically useful? In Gastroenterologia, Hepatologia y Endoscopia basadas en la evidencia. Editors, JKY Furusho, JFS Avila, EL Mendez, MU Esquivel. Fundacio Mexicana para la Salud, 2008. Friedman SL. How can we stop hepatic fibrogenesis?. Kluwer publishers, Lancaster, UK, 2008.